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1 Definitions of events/outcomes 
 1.1 Deep vein thrombosis (DVT), symptomatic, by/at day 7 
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1.4 Feeding status 
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1.6 Hypertension, symptomatic by day 7 
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1.9 Neurological deterioration, clinical by day 7 
1.10 Pulmonary embolism, symptomatic by day 7 
1.11 Recurrent stroke, symptomatic by day 7 
1.12 Intracranial haemorrhage, symptomatic by day 7 
1.13 Time at home 
1.14 Venous thromboembolism, symptomatic by day 7 
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 2.1 Geographical region 
 2.2 Haemodynamic variables, calculated 
 2.3 Acute Stroke Unit 
2.4 Stroke Rehabilitation Unit 
2.5 Final diagnosis 
2.6 Date of death 
2.7 EQ-5D and Health Utility Status 
2.8 Protocol violations 
 2.8.1 All analyses 
2.8.2 GTN vs no GTN 
2.8.3 Continue vs stop pre-stroke antihypertensive medication 
2.9 CT/MR image adjudication 
 2.9.1 Infarct visibility 
2.9.2 Lesion site 
2.9.3 Sub-territory sites 
 
Appendix C Tables and figures in primary publications 
 
Authors 
1 Table 1. Baseline characteristics 
 1.1 Both GTN/no GTN and Continue/Stop 
 1.2 Continue vs stop pre-stroke antihypertensive medications 
2 Table 2. Compliance 
2.1 Both GTN/no GTN and Continue/Stop 
3 Table 3. Outcomes 
 3.1 Both GTN/no GTN and Continue/Stop 
4 Table 4. Serious adverse events 
 4.1 Both GTN/no GTN and Continue/Stop 
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 11.1 Both GTN/no GTN and Continue/Stop 
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APPENDIX A 
 
1 INTRODUCTION 
 
High blood pressure (BP) is present in 70% or more of patients with acute ischaemic 
stroke and spontaneous intracerebral haemorrhage (ICH).1 Affected patients have a 
worse outcome, whether judged as early recurrence, death within a few weeks, or 
combined death and dependency after several months.1-4 Lowering BP might therefore 
reduce these events and improve functional outcome providing that cerebral perfusion is 
not reduced in the presence of dysfunctional cerebral autoregulation. However, recent 
large trials have been inconclusive in their results.5,6 
 
Nitric oxide (NO) donors are candidate treatments for acute stroke; NO is a cerebral and 
systemic vasodilator, modulates vascular and neuronal function, and inhibits apoptosis.7 
Preclinical studies of cerebral ischaemia have found that NO donors reduce stroke lesion 
size, and improve regional cerebral blood flow and functional outcome.8 Five small 
clinical studies of NO donors have been performed, these involving a total of 208 
patients with recent stroke. Intravenous sodium nitroprusside reduced BP without 
altering CBF, and exhibited antiplatelet effects (thereby precluding its use in 
spontaneous ICH).9 Four pilot trials of transdermal glyceryl trinitrate (GTN) found that it 
lowered BP by approximately 8%; did not alter platelet function (and so could be given 
in ICH); did not alter middle cerebral artery blood flow velocity or regional cerebral blood 
flow; improved aortic vascular compliance; and could be given to patients with 
dysphagia.10-13 No safety concerns were present in these studies, and in one small trial 
ultra-acute treatment with GTN was associated with an improved functional outcome.13,14 
 
On the basis of this pre-clinical and clinical data showing feasibility, tolerability and 
apparent safety of GTN, and the potential for efficacy, the large ‘Efficacy of Nitric Oxide 
in Stroke’ (ENOS) trial was started and is ongoing. ENOS is assessing, in a partial 
factorial prospective randomised open blinded-outcome design, whether to lower BP with 
GTN (versus no GTN), and whether to continue (versus stop) pre-stroke 
antihypertensive therapy. The trial commenced in 2001 and its protocol was published in 
2006.15 Several non treatment-related and blinded analyses of the ENOS database have 
been published since the start of the trial.16-20 The independent Data Monitoring 
Committee have assessed the trial every 6 months and on each occasion recommended 
that the trial should continue. 
 
 
2 PRIMARY RESEARCH QUESTIONS 
 
1. Does transdermal glyceryl trinitrate (GTN, 5 mg daily for 7 days), when given acutely 
after stroke, reduce death or dependency at 90 days, as compared to no GTN. This 
question applies to all randomised patients. 
 
2. Does continuing pre-stroke antihypertensive medications reduce death or dependency 
at 90 days, as compared to stopping these medications for 7 days. This question applies 
to those randomised patients who were taking antihypertensive medications immediately 
prior to stroke onset (anticipated to be ~50% of the whole trial population). 
 
 
3 TRIAL DESIGN 
 
3.1 Design 
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ENOS is an international multicentre prospective randomised single-blind blinded-
endpoint controlled partial-factorial trial with centralised randomisation (stratification 
and minimisation) to ensure allocation concealment and reduce bias. 
 
3.2 Trial population 
 
Previously independent adult patients who are conscious, have residual limb weakness, 
have systolic blood pressure between 140-220 mmHg, and are within 48 hours of stroke 
onset, are eligible for enrolment. The full inclusion-exclusion criteria are given in the 
protocol.15 
 
3.3 Randomisation 
 
All patients are randomised to GTN vs no GTN. Those patients who are taking 
antihypertensive medications immediately prior to their stroke are also randomised to 
continue or stop this. As a result, there are 6 treatment groups, with a working sample 
size totalling 3,800 patients (which exceeds the grant-funded 3,500 patients), and 
approximately 50% of patients on BP drugs before their stroke. 
 
 Pre-stroke BP drugs No pre-stroke 
BP drugs 
Size by row 
 Continue Stop   
GTN 475 475 950 1,900 
No GTN 475 475 950 1,900 
Size by column 950 950 1,900 3,800 
 
The process of randomisation includes (1) stratification; (2) minimisation; and then (3) 
simple randomisation. Stratification and minimisation allow for improved matching at 
baseline, stratification allows variable categories to be treated as trials in their own right, 
minimisation increases statistical power,21 and simple randomisation reduces 
predictability. The minimisation variables will be used for adjustment of the primary and 
secondary analyses. 
 
3.3.1 Stratification 
i. Immediate prior use of antihypertensive treatment. 
ii. Stroke pathological type (ischaemic stroke [IS]/unknown, spontaneous 
intracerebral haemorrhage [ICH]) 
iii. Country 
3.3.2 Minimisation 
i. Age (<70 years, >70 years) 
ii. Sex (female, male) 
iii. History of hypertension (no, yes) 
iv. History of previous stroke (no, yes) 
v. Diabetes mellitus (no, yes) 
vi. Current use of nitrate therapy (no, yes) 
vii. Stroke severity (Scandinavian Stroke Scale,22 SSS >30, <30) 
viii. Total anterior circulation syndrome (no, yes) 23 
ix. Systolic BP (<160, >160 mmHg) 
x. Treated with rt-PA prior to randomisation (yes, no) 
xi. Feeding status (other, iv fluids/nothing) 
xii. Time to randomisation (>24 hours, <24 hours) 
3.3.3 Simple randomisation 
On 5% of patients at time of minimisation. 
 
3.4 Minimising bias 
CONFIDENTIAL: ENOS SAP APPENDIX 20130811 
 Page 8 of 80 
 
Multiple measures are taken to minimise bias: central data registration with real-time 
on-line validation; concealment of allocation; patient blinding to GTN (gauze dressing 
over GTN patch or equivalent area of skin); blinded central telephone assessment of 3 
month outcome by staff at National Coordinating Centres; assessment of patient recall of 
treatment;11 blinded adjudication of CT scans/SAEs; exclusion of patients enrolled in 
other trials; analysis by intention-to-treat; and adjustment for minimisation factors and 
non-randomised treatment (alteplase). 
 
3.5 Ethics and regulatory approvals 
 
ENOS is run according to the principles of the Declaration of Helsinki and ‘Good Clinical 
Practice'. The trial was approved by national competent authorities (where applicable), 
e.g. European Medicines Agency (EudraCT number 2004-003870-27, date 1/10/2004), 
UK Medicines & Healthcare products Regulatory Authority (formerly Medicines Control 
Agency, reference MF8000/10820, date 16/2/2001); national and local research ethics 
committees (REC), e.g. UK Trent REC (reference MREC/01/4/046, date 3/9/2001), 
Scottish 1 REC (reference MREC/02/0/121, date 7/1/2003); and adopted by the 
Australian, Canadian, and UK NIHR Stroke Research Networks (date 25/4/2006). Trial 
funding from BUPA Foundation, and the Medical Research Council (grant: G0501797, 
awarded 26/4/2006) followed external peer review. 
 
 
4 STATISTICAL ANALYSIS PLAN (SAP) 
 
4.1 Original SAP 
 
The trial was originally designed to recruit 5,000 patients so as to detect an absolute risk 
reduction in the binary outcome of death or dependence (modified Rankin Scale, 
mRS>2) of 5% from 50% in the control group to 45% in the GTN group, with power 
90%, significance 5%, and allowance for losses to follow-up. The original planned 
method of analysis, as published in the protocol paper,15 was to compare the proportion 
of participants who were dead or dependent at 90 days between the treatment groups. 
 
4.2 Revised SAP 
 
Recent research has shown that binary analysis of the 7-level mRS is sub-optimal and 
that statistical power is increased by using all the data at each level by comparing 
differences in distribution across the whole scale between the treatment groups.24 This 
approach is now recommended by the European Stroke Organisation.25 A further, and 
additional, increase in statistical power is achieved by incorporating key prognostic 
baseline variables as covariates.26 Other groups have presented similar findings and 
used this approach.27-29 
 
Hence, the primary analysis of the mRS in ENOS will utilise the shift approach, as 
analysed using ordinal logistic regression, with adjustment for covariates, with 
comparison between treatment groups (GTN/no GTN; continue/stop pre-stroke BP 
medications). The overall proposal to change the method of analysis of the primary 
outcome from binary to ordinal was first presented to, and agreed by, the Trial Steering 
Committee in January 2008, and confirmed in 2009. An early draft version of this SAP, 
highlighting this change, was posted on the trial website in April 2009. 
 
This change to the design of ENOS was made without knowledge of any interim analysis 
that split patients by treatment group. The statistician who prepares analyses for the 
independent Data Monitoring Committee (DMC), and the DMC themselves, were not 
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involved in the writing of this statistical analysis plan (SAP), and have not seen or 
commented on it. 
 
4.3 Outcomes and their analysis 
 
All outcomes will be assessed by: 
• GTN versus no GTN 
• Continue versus temporarily stop pre-stroke antihypertensive medication 
 
4.3.1 Analysis populations 
The following populations of patients are defined for analyses and take account that the 
trial is single-blind in design. 
 
4.3.1.1 Intention-to-treat safety population 
All randomised participants with vital status recorded. 
 
4.3.1.2 Intention-to-treat efficacy population 
All randomised participants with the primary outcome recorded. 
 
4.3.1.3 Per protocol population 
All randomised participants with the primary outcome recorded and who did not have a 
relevant protocol violation as defined in Appendix B.2.8. A key criterion is that an 
included patient must have received at least 4 days of treatment (or died before this). 
 
4.3.1.4 Analyses by population 
All efficacy analyses will be performed on the intention to treat population. A separate 
‘per protocol’ analysis will be performed on the primary and key secondary outcomes. 
Safety analyses will be performed on the safety population. 
 
4.3.2 Missing data, and death 
 
Missing data will not be imputed. Participants who die will be assigned discrete values for 
outcome measures with a value worse than any living value (as is standard for mRS, 
BI). This avoids giving death the same value as the worst possible outcome when alive 
(best to worst), and ensures that patients who die are included in all analyses. The EQ-
5D Health Utility State (HUS) gives death a score of 0. 
• Modified Rankin Scale (mRS), 0 to 5 with death = 6 
• Barthel Index (BI), 100 to 0 with death = -5 
• Scandinavian Stroke Scale (SSS), 58 to 0 with death = -1 
• EQ-5D HUS, 1 to -0.594 with death = 0 
• EQ-VAS (visual analogue scale), 100 to 0 with death = -1 
• Zung Depression Scale (ZDS), 25 to 100 with death = 102.5 
• Telephone Interview for Cognitive Status (TICS), 39 to 0 with death = -1 
• Verbal fluency (animal naming), ∞ to 0, with death = -1 
• Telephone Mini Mental Status Exam (t-MMSE), 18 to 0, with death = -1 
 
Patients who are still in hospital at day 90 will have a length of stay assigned at 110 
days. Similarly, death will be censored at day 110. 
 
4.3.3 Statistical assumptions 
 
4.3.3.1 Proportionality of odds 
The treatment effects on ordered categorical data will be compared using ordinal logistic 
regression (OLR) with adjustment for the prognostic covariates as listed in 3.3.2, plus 
use of alteplase. OLR assumes proportionality of odds and this will be tested using a 
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likelihood ratio test. If the proportional odds assumption is not met, OLR will still be used 
and the lack of proportionality of odds highlighted. In this circumstance, the odds ratio 
may remain relevant (and probability value accurate) providing the treatment effect is 
relatively consistent across the spread of mRS scores. 
 
4.3.3.2 Alpha spending 
The Data Monitoring Committee performs safety assessments using the ‘3 standard 
deviation’ approach; hence, no significant spending of alpha has occurred during the 
trial. All analyses will be two-tailed and a p-value of <0.05 will denote statistical 
significance; 95% confidence intervals will be provided. Adjustment for multiple 
comparisons will not be performed but all contrasts will be declared. 
 
The primary and secondary outcomes follow here. Although not all the secondary 
outcomes will be presented in the two primary papers (GTN vs no GTN, continue vs stop 
pre-stroke antihypertensive medication), they will be used in secondary papers and are 
given here for completeness. 
 
4.3.3.3 mRS levels 
Although some previous studies (e.g. SAINT-I/II, ECASS-3 29-31) combined death with 
severe disability (i.e. mRS categories 5 and 6 were combined), these mRS categories will 
be analysed separately in ENOS since blood pressure treatment may influence both 
mortality and disability. 
 
4.4 Primary outcome 
 
4.4.1 Primary outcome measure 
The seven-level ordered categorical modified Rankin Scale (mRS):22,32 
0 No symptoms at all. 
1 No significant disability, despite symptoms; able to carry out all usual duties and 
activities. 
2 Slight disability; unable to carry out all previous activities but able to look after 
own affairs without assistance. 
3 Moderate disability; requiring some help, but able to walk without assistance. 
4 Moderately severe disability; unable to walk without assistance and unable to 
attend to own bodily needs without assistance. 
5 Severe disability; bedridden, incontinent and requiring constant nursing care and 
attention. 
6 Dead. 
 
4.4.2 Primary outcome analysis 
All 7 levels of the mRS will be used with analysis by OLR with adjustment for baseline 
covariates:24-26 
• Age; sex (female, male); pre-morbid mRS; history of previous stroke (no, yes); 
diabetes mellitus (no, yes); current use of nitrate therapy (no, yes); stroke severity 
(Scandinavian Stroke Scale, SSS); total anterior circulation syndrome (no, yes); 
stroke pathological type (non, IS, ICH); systolic BP (SBP); treated with rt-PA (yes, 
no); feeding status (oral, non oral); time onset to randomisation. 
• The comparison of GTN vs no GTN will also include the covariate for Continue vs stop 
pre-stroke antihypertensive medication. 
• The comparison of Continue vs stop pre-stroke antihypertensive medication will also 
include the covariate for GTN vs no GTN. 
Covariate adjustment with ordered categorical (mRS) or continuous (age, SSS, SBP, 
time) variables will use the original, not dichotomised, data. 
 
4.4.3 Primary outcome subgroup analyses 
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The effect of the two interventions (GTN versus no GTN; continue versus temporarily 
stop pre-stroke antihypertensive medication) on the primary outcome will be performed 
within the following pre-specified subgroups of participants. Subgroup analyses will be 
performed on mRS using ordinal logistic regression. An interaction test between each 
subgroup and treatment will be performed. 
 
4.4.3.1 Primary publications 
a) Age - ≤70, >70 years 
b) Sex – female, male 
c) History of prior stroke – no, yes 
d) Stroke severity (/58) – SSS >40, 30-40, <30 
e) Oxfordshire Community Stroke Project Classification 23 – LACS, POCS, PACS TACS  
f) Stroke pathological type – ischaemic stroke, unknown, ICH 
g) Mean blood pressure (mmHg) – SBP ≤160, 161-180, 181-200, >200 
h) Atrial fibrillation/flutter – absent, present 
i) Non-oral feeding (surrogate for dysphagia) – absent, present 
j) Carotid stenosis (ipsilateral %) – 0-49, 50-69, 70-99, 100 (as determined locally) 
k) Time to randomisation (hours) - ≤6.0, 6.1-12.0, 12.1-24.0, 24.1-36, >36 
l) Treatment with alteplase – present, absent 
 
Additionally, for GTN versus no GTN 
a) History of recent nitrate exposure – no, yes 
b) Pre-stroke antihypertensive medication randomisation – not relevant, continue, 
stop 
 
Additionally, for continue versus stop pre-stroke antihypertensive medication: 
a) Pre-stroke antihypertensive class – angiotensin-converting enzyme inhibitor, 
angiotensin-II receptor antagonist, renin inhibitor, β-blocker, calcium-channel 
blocker, diuretic, α-blocker, centrally acting agent, other (participants may appear 
in more than one subgroup) 
b) Number of classes of antihypertensive drugs pre-stroke – 1, 2, 3, 4, 5, >5 
c) GTN randomisation – GTN, no GTN 
 
4.4.3.2 Secondary publications 
In secondary papers, the effect of treatment on mRS will also be assessed in additional 
sub-groups: 
a) Geographical region (section B.2.1) 
b) TOAST criteria (small vessel, large vessel, cardioembolism, dual pathology, other) 
c) Carotid stenosis (>=50%) – none, contralateral, ipsilateral, bilateral 
d) Old lesion on baseline neuroimaging – no, yes 
e) Lesion size – 1, 2, 3, 4 (Appendix B, section 2.9.2) 
f) Mass effect – 0,1 vs 2-4 vs 5,6 (Appendix B, section 2.9.3) 
 
4.4.4 Sensitivity analyses 
Several sensitivity analyses will be performed as a reference for the primary analysis. 
The method of analysis is given: BLR: binary logistic regression; OLR: ordinal logistic 
regression 
a) mRS, unadjusted       OLR 
b) mRS, with additional adjustment for Geographical region OLR 
c) Dead or dependent (mRS 3-6, adjusted)   BLR 
d) Dead or dependent (mRS 3-6, unadjusted)   BLR 
e) Global outcome, mRS>1 and BI <95, adjusted  Wald test 33,34 
Comparison (d) is the original trial primary outcome prior to switching to an ordinal 
analysis. 
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4.5 Secondary outcomes 
 
Secondary outcomes are listed by their timing. Analysis methods will include: MLR: 
multiple linear regression; analyses will be adjusted as in section 4.4.2 and also 
performed unadjusted for completeness. 
 
4.5.1 Events by day 7 (end of treatment) 
a) Death         BLR 
b) Symptomatic intracranial haemorrhage   BLR 
c) Major extracranial haemorrhage     BLR 
d) Symptomatic recurrent stroke     BLR 
e) Impairment (SSS)       MLR 
f) Impairment (calculated NIHSS 35)    MLR 
g) Clinical neurological deterioration    BLR 
h) Neurological deterioration 22     BLR 
i) Headache that required treatment    BLR 
j) Symptomatic hypotension that required treatment  BLR 
k) Symptomatic hypertension that required treatment  BLR 
l) Symptomatic venous thromboembolism   BLR 
 
4.5.2 Hospital events (collected at discharge or on death) 
a) Length of stay in hospital      MLR 
b) Discharge disposition (death/institution/home)  OLR 
 
4.5.3 Outcome at 90 days (end of follow-up) 
This are determined centrally by a telephone call between the patient (or carer) and an 
assessor blinded to treatment and earlier clinical information: 
a) Death (censored by day 110)     BLR 
b) Time to death (censored at 110 days)    Cox regression (Kaplan 
Meier curve) 
c) Barthel Index (BI)       MLR 
d) Dead or disabled (BI <60)     BLR 
e) Quality of life (HUS derived from EQ-5D)   MLR 
f) Quality of life (EQ-5D VAS)     MLR 
g) t-MMSE        MLR 
h) TICS-M        MLR 
i) Verbal fluency       MLR 
j) Zung Depression Scale (ZDS, mood)    MLR 
 
4.6 Safety analyses – Serious Adverse Events 
 
Safety analyses are listed together with their preferred method of analysis. All SAEs 
reported by the investigator are adjudicated by a member of the independent 
adjudicator panel who is blinded to treatment. The adjudicated SAE categorisation will 
be presented for all analyses. The number of participants with a SAE rather than the 
number of SAE will be analysed. Comparisons will be performed on all patients. 
 
4.6.1 SAEs by day 10 (7 days of treatment + 3 days of washout) 
a) Serious adverse event, number of patients   BLR 
 
4.6.2 SAEs by day 90 (end of follow-up) 
a) Serious adverse event, number of patients   BLR 
 
Serious adverse events by 90 days will be tabulated as the number of participants with 
an event in each treatment group, and the number of events in each treatment group, 
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by the following subgroups. BLR will be used to identify any differences between 
treatment groups. 
a) System organ class 
b) Event category within system organ class 
c) Time of onset relative to treatment (before, during, after)  
d) Median time to event by event category 
e) Severity (mild, moderate, severe) 
f) Relationship to study drug (definitely not, unlikely, possibly, probably, definitely) 
g) Fatal, non-fatal 
h) Fatal by event category 
 
Common serious adverse events that will be reported are listed in Appendix C table 4. 
 
4.7 Compliance 
 
Compliance with allocated treatment will be tabulated. Patients receiving at least the 
first 4 doses of treatment are considered to have received full treatment. The following 
data will be presented separately for GTN vs. no GTN, and continue vs. temporarily stop 
pre-stroke antihypertensive medications 
a) Number (%) of participants who received all 7 days of allocated treatment 
b) Number (%) of participants who received at least the first 4 days of allocated 
treatment 
c) Number (%) of participants who received at least the first allocated treatment 
d) Number (%) of participants who did not receive any of the allocated treatment 
 
In those participants who did not receive all the first 4 days of allocated treatment, the 
reason for non-compliance will be given: 
a) Discharged before day 4 
b) Physician withdrew participant 
c) Adverse event, unacceptable 
a. Headache 
d) Serious adverse event 
e) Consent withdrawn by participant or relative 
f) Death 
g) Other reason 
 
 
Note: Patients discharged before day 7 were given their remaining part of their course of 
GTN to complete at home. 
Reasons for non-compliance All GTN No GTN 
Reasons for non-compliance All Continue Stop 
Participants randomised    
Compliance    
   Received all 7 days of treatment    
   Received first 4 days of treatment    
   Received first treatment    
   Did not receive any randomised treatment    
Non-compliance by day 4 (%)    
   Discharged    
   Physician withdrew participant    
   Adverse event, unacceptable    
      Headache    
   Serious adverse event    
   Consent withdrawal by participant or relative    
   Death    
   Other    
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4.8 Analysis methods 
 
Data variables will, in the main, be analysed using binary logistic regression (BLR), Cox 
logistic regression (CLR); ordinal logistic regression (OLR) or multiple logistic regression 
(MLR), thereby allowing adjustment for baseline measures and other covariates (as 
listed partially in section 4.4.3). 
 
4.8.1 Clinical variables 
• BLR: Death; Death or deterioration (day 7); Recurrence (day 7); Symptomatic 
intracranial bleed (sICH); Discharged to or at Home 
• CLR: Death 
• OLR: Modified Rankin Scale (mRS) [/6];  
• MLR: Scandinavian Stroke Scale (SSS, /58); Length of stay in hospital; Barthel Index 
(BI, /100); telephone Mini-Mental State Examination (tMMSE); Telephone Interview 
of Cognition Scale (TICS, /39); Animal naming (/∞); Zung Depression Scale (ZDS, 
/100); Health Utility State (HUS, /1); EuroQoL Visual Analogue Scale (EQ-VAS, /100) 
 
4.8.2 Imaging variables 
• BLR: Loss of grey-white definition; Loss of basal ganglia outline; Hypodensity; Mass 
effect; ICH mean radial expansion > 1mm; Second lesion; Hyperdense artery 
• OLR: Lesion site; Lesion size: MCA, lacunar, cerebellum or brainstem; Mass effect, 
degree [/6]; Haemorrhagic Transformation of Infarct; Hypoattenuation; Mass effect 
score (greatest of Uncal> shift> ventricular> sulcal); Middle Cerebral Artery 1/3 (if 
MCA, >1/3, <1/3, no lesion); ASPECTS score; ICH diameter, max – adjudicated; ICH 
shape [/5]; ICH density [/5]; IVH Graeb [/12];36 IVH modified Graeb [/32];37 
• MLR: Volume (ABC/2), absolute (ml); Volume (ABC/2), relative (%); Diameter, max 
(cm); Haematoma shape index; Haematoma mean density; Haematoma density 
index; IVH volume 
 
4.8.3 Procedures 
The two primary papers will be analysed using two separate sets of statistical 
programmes, one written specifically for the purpose and the other based on the Data 
Monitoring Committee report. A further analysis of a sub-set of the main results will be 
performed using a third statistical programme. This will allow the results to be cross-
checked. 
 
To maximise recruitment, maximise time for analysis and interpretation of the results, 
and allow presentation of the final results at the European Stroke Conference in early 
May 2014, a soft-lock and preliminary analysis will be performed once the last patient 
has had their final outcome recorded in early January 2014. Following final data cleaning 
on the last patients to be recruited, a hard-lock will be performed in late January/early 
February and the results of this considered by the Trial Steering Committee in mid 
February 2014. The preliminary interpretation will be performed after soft-lock by PMB, 
NS, JW and SP; they will not be involved in resolving any final queries to maintain the 
integrity and blinding of the final database. The approach of soft-lock then hard-lock is a 
standard approach in large trials and does allow more time to be spent on considering 
the results of a trial, their interpretation and presentation for publication. 
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APPENDIX B. DEFINITIONS 
 
1 DEFINITIONS OF EVENTS/OUTCOMES 
 
1.1 Deep vein thrombosis (DVT), symptomatic, by/at day 7 
The clinical suspicion of DVT will need confirmation by either venography or ultrasound 
examination. 
 
1.2 Disposition 
Disposition at 90 days and discharge disposition is categorised as death, institution or 
home. 
• Institution refers to warden controlled, residential home, care home, nursing home, 
still an inpatient, or readmitted to hospital. 
• Home refers to home alone, home with spouse/carer and carer’s home. 
 
1.3 Extracranial haemorrhage, major 
Clinically overt bleeding associated with one or more of: 
• Transfusion of > 2 red cell units of blood  
• A fall in haemoglobin of 20 g/l (=2 g/dl, = 1.24 mmol/l)  
• Bleeding into retroperitoneum, intraocular space or major joint  
• Bleeding leading to permanent cessation of trial interventions 
 
1.4 Feeding status 
Feeding status will be defined as: 
• Oral: normal diet, soft diet 
• Non-oral: nasogastric tube fed, PEG-tube fed, iv/sc fluids, no feeding/fluids 
 
1.5 Headache, requiring treatment by day 7 
A headache occurring during GTN/no GTN treatment that necessitates intervention, 
including withdrawing GTN/no GTN treatment. 
 
1.6 Hypertension, symptomatic by day 7 
A rise in blood pressure necessitating intervention to reduce it. 
 
1.7 Hypotension, symptomatic by day 7 
A symptomatic fall in blood pressure of > 20% as compared with baseline necessitating 
intervention with intravenous colloid or crystalloid (saline). 
 
1.8 Neurological deterioration, by day 7 
A reduction in SSS of >4 points, or decrease in consciousness level by >2 points, as 
compared with baseline.22 
 
1.9 Neurological deterioration, clinical by day 7 
Neurological deterioration determined clinically.  
 
1.10 Pulmonary embolism (PE), symptomatic by day 7 
The clinical suspicion of PE will need confirmation by either high-probability ventilation-
perfusion lung scintigraphy, pulmonary angiography, inconclusive V/Q scan and DVT, or 
lead to death. 
 
1.11 Recurrent stroke, symptomatic, by/at day 7 
Classified as haemorrhagic or ischaemic (if documented by CT/MR scan or autopsy), or 
of unknown type. The time from stroke onset and side will be noted. (This definition 
deliberately does not attempt to differentiate true recurrence from extension of the 
presenting lesion since this is clinically and radiologically difficult unless recurrence 
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occurs in a new arterial territory.) 
 
1.12 Intracranial haemorrhage, symptomatic by day 7 
Neurological deterioration or death, associated with intracranial haemorrhage found on 
CT/MR scan or autopsy. 
 
1.13 Time at home 
Calculated as time from date of discharge to day 90 or death if earlier; those who die in 
hospital or are discharged to a non-home setting are given a score of zero. Readmission 
to hospital is not counted in this time. 
 
1.14 Venous thromboembolism, symptomatic by day 7 
Symptomatic DVT and/or symptomatic pulmonary embolism 
 
 
2 OTHER DEFINITIONS AND NOTES 
 
2.1 Geographic region 
This is categorised into Africa, America north, Asia east, Asia south, Asia south-east, 
Australasia, British Isles, and Europe. Each geographical region is defined as the 
following countries, each of which have randomised at least one participant into the 
ENOS trial: 
a) Africa: Egypt 
b) America, north: Canada 
c) Asia, east: China, Hong Kong 
d) Asia, south: India, Sri Lanka     
e) Asia, south-east: Malaysia, Philippines, Singapore 
f) Australasia: Australia, New Zealand  
g) British Isles: Eire, UK 
h) Europe: Denmark, Georgia, Greece, Italy, Norway, Poland, Romania, Spain, 
Sweden 
 
2.2 Haemodynamic variables, calculated 
These are calculated from SBP, diastolic blood pressure (DBP) and HR measurements at 
baseline (day 0) and on days 1-6. Mean, peak, and standard deviation (SD), of 
SBP/DBP/HR are calculated from available measurements at that time point. 
 
Coefficient of Variation, CV=SD/mean. 
 
a) SBP, mean 
b) SBP, peak 
c) SBP, intra-visit variability = SD of SBP separately at each time point 
d) SBP, CV 
e) DBP, mean 
f) DBP, peak 
g) DBP, intra-visit variability = SD of DBP separately at each time point 
h) DBP, CV 
i) HR, mean 
j) HR, peak 
k) HR, intra-visit variability = SD of HR separately at each time point 
l) HR, CV 
m) Mean arterial pressure (MAP) = mean DBP + (mean SBP / 3) 
n) Mean pressure (MP) = (mean DBP + mean SBP) / 2 
o) Pulse pressure (PP) = mean SBP – mean DBP 
p) Pulse pressure index (PPI) = PP / MAP 
CONFIDENTIAL: ENOS SAP APPENDIX 20130811 
 Page 17 of 80 
q) Rate-pressure product (RPP) = mean SBP x mean HR 
r) Mean SBP across days 1-4 
s) Inter-visit Variability (SBP-inter SD) = SD of SBP across days 1-4 
t) CV SBP across days 1-4 
u) SBP peak across days 1-4 
 
2.3 Acute Stroke Unit (ASU) 
A high-dependency nursing unit (or area) caring only/mainly for patients with acute 
stroke and providing close monitoring of neurological and vascular signs. 
 
2.4 Stroke Rehabilitation Unit (SRU) 
A dedicated rehabilitation unit (or area) caring only/mainly for patients with recent 
stroke and providing multi-disciplinary therapy (e.g. physiotherapy, occupational 
therapy, speech & language therapy). 
 
2.5 Final diagnosis: ischaemic stroke, ICH, unknown type of stroke, non-stroke 
The final diagnosis for the qualifying event will be determined using information from the 
recruiting site based on the clinical presentation, history of recovery and interpretation 
of the brain scan. The resulting diagnosis will be compared with that from central 
adjudication of the baseline brain scan. If there is a discrepancy between site and 
adjudication, the site will be contacted to clarify the diagnosis and the scan reviewed 
centrally by JMW; ultimately the site’s final diagnosis will be used if agreement cannot 
be obtained. 
 
Final diagnosis will comprise one of the following: ischaemic stroke (which includes a 
normal CT brain scan), ICH, stroke of unknown pathological type, or non-stroke (e.g. 
tumour, abscess, subdural bleed). 
 
Final diagnosis will be determined using the following source(s): 
1. Hospital event form (completed at discharge or death: final diagnosis question). If 
this is unavailable use 2. 
2. Day 7 form (baseline CT/MRI scan result question). If this is unavailable use 3. 
3. Baseline form – as used for randomisation (baseline CT/MRI scan result question). If 
this is unavailable use 4. 
4. If the diagnosis of stroke is not known according to the data sources above (e.g. due 
to early death and no autopsy), then the diagnosis will be assigned as ‘Stroke, type 
unknown’. 
 
2.6 Date of death 
Dates of death have multiple sources and these are ranked for determining the date (in 
case a particular source is missing the information): 
1. MRIS/ONS feedback, if UK patient 
2. Serious adverse event form 
3. Hospital event form 
4. Day 7 form 
If there is a discrepancy in the recorded date then the site are approached to confirm 
the correct date. 
 
2.7 EQ-5D and Health Utility States (HUS) 
EQ-5D is a measure of health status and is composed of the EQ-5D descriptive system 
and EQ visual analogue scale (EQ VAS). The EQ VAS is a self-rated scale from 0 (worst 
imaginable health state) to 100 (best imaginable health state). The EQ-5D descriptive 
system has 5 dimensions: mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. Each dimension has 3 levels; no problems (level 1), some problems 
(level 2), severe problems (level 3).38  
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There are 243 possible health states. Each health state is referred to by a 5 digit code, 
e.g., 11111. The EQ-5D health states can be converted into a single summary index 
ranging from 1.00, i.e. full health (11111), to -0.594 (33333, worst possible state using 
the UK version of the time trade-off algorithm), with death assigned to 0.38 The 
conversion is made by applying the formula in Table 5, which deducts weights applied to 
each dimension from the starting value of 1. The UK version of the EQ-5D index 
algorithm using the time trade off value set will be used for all patients.19 
 
EQ-5D index scoring algorithm (Time trade-off: UK version) 
 Weight 
Full health (11111) 1 
At least one 2 or 3  -0.081 
At least one 3 -0.269 
Mobility  
   Score 2 -0.069 
   Score 3 -0.314 
Self-care  
   Score 2 -0.104 
   Score 3 -0.214 
Usual activities  
   Score 2 -0.036 
   Score 3 -0.094 
Pain/discomfort  
   Score 2 -0.123 
   Score 3 -0.386 
Anxiety/depression  
   Score 2 -0.071 
   Score 3 -0.236 
    
For example, a health state of 32211 will convert to 0.196 (=1-0.81-0.269-0.314-0.104-
0.071). 
 
2.8 Protocol violations 
For per protocol analyses, patients who have one or more of the following protocol 
violations will be excluded from the per protocol population: 
 
2.8.1 All analyses 
• Failure to obtain consent or assent 
• Antihypertensive medication received post-stroke and pre-randomisation 
• Age<18 years 
• Randomised >48 hours 
• No limb weakness at any point in presentation 
• Glasgow Coma Scale (GCS) <8 at baseline 
• Systolic BP <140 mmHg or >220 mmHg at baseline 
• Final diagnosis non-stroke 
• Final diagnosis unknown because no neuroimaging or autopsy 
 
2.8.2 GTN vs no GTN 
• Failure to stop pre-stroke nitrates 
• No GTN received for first 4 days if randomised to GTN 
• GTN received in first 4 days if randomised to no GTN 
 
2.8.3 Continue vs stop pre-stroke antihypertensive medication 
• Failure to identify pre-stroke antihypertensive medication 
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• Antihypertensives received during first 4 days if randomised to stop 
• Antihypertensives not received during first 4 days if randomised to continue 
 
2.9 CT/MR image adjudication 
All patients should have a diagnostic CT or MRI scan, ideally before randomisation or at 
least within one week of randomisation. A second CT or MRI scan is performed at the 
end of treatment (7 ± 2 days, or earlier if clinically warranted) to allow the effect of 
treatment on stroke lesion development to be assessed; principal investigators can opt 
in or out of the second scan. Both baseline and second CT/MRI scans are assessed by an 
independent adjudicator blinded to treatment assignment. Lesion size is assessed by an 
independent assessor, i.e. not by the investigator. 
 
2.9.1 Infarct visibility (as per IST-3 scheme ©JMW 2012 39) 
Infarct size is coded (small=1 through to large=4) using adjudicated data for both baseline 
and, where done, day 7 CT/MR scans. 
 
2.9.2 Site        Condensed code 
M† =MCA = any lesion in the MCA territory   see 2.13.10.2 below 
AS =Infarct of up to half of ACA territory   1 
AL =Infarct of more than half of ACA territory  2 
PS =Infarct of up to half of PCA territory   1 
PL =Infarct of more than half of PCA territory  3 
MAS=M+AS†       3 if MCA 1 or 2; 4 if MCA 3 or 4 
MAL=M+AL†       3 if MCA 1 or 2; 4 if MCA 3 or 4 
MPS=M+PS†       3 if MCA 1 or 2; 4 if MCA 3 or 4 
MPL=M+PL†        3 if MCA 1 or 2; 4 if MCA 3 or 4 
MAP=Infarct of whole MCA, ACA and PCA territories 4 
L† =Lacunar       1 
B† =Borderzone       1 
C† =Cerebellum       see b below 
S† =Brainstem       see b below 
CS† =Cerebellum and brainstem     3 
 
† code sub-territory sites as in 2.13.10.2 
 
2.9.3 Sub-territory sites 
 
MCA sub-territory codes 
1=small cortical infarct      1 
2=basal ganglia infarct (>2x2x2cm)    2 
3=infarct of white matter lateral to lateral ventricle (>2x2x2cm) 2 
4=infarct of anterior half of peripheral MCA territory 2 
5=infarct of posterior half of peripheral MCA territory 3 
6=infarct of whole of peripheral MCA territory  3 
7=6+infarct of lateral part of basal ganglia   4 
8=infarct of whole of MCA territory    4 
 
Lacunar/Borderzone sub-territory codes   all 1 
  9=lacune in internal capsule/lentiform 
10=lacune in internal border zone  
11=lacune in centrum semiovale 
12=lacune in thalamus 
13=lacune in brainstem, including pons (not shown) 
14=anterior (mainly) border zone 
15=posterior (mainly) border zone 
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Cerebellum sub-territory codes 
16=small cortical (not shown)     1 
17=<1/2 hemisphere (medium) (not shown)   2 
18=>1/2 hemisphere (not shown)    3 
 
Brainstem sub-territory codes 
19=small, i.e.<1/2 medulla (not shown)   1 
20=extensive, i.e. pons + medulla (not shown)  2 
 
Degree of mass effect codes 
0=no swelling 
1=effacement of sulci overlying stroke 
2=1+minor effacement of adjacent lateral ventricle 
3=1+complete effacement of adjacent lateral ventricle 
4=1+effacement of lateral and third ventricle 
5=4+shift of the midline away from side of ventricle 
6=5+effacement of basal cisterns 
 
2.9.4 Infarcts 
 
Loss of grey/white matter cortex definition  yes/no 
 
Loss of basal ganglia outline    yes/no 
 
Hypodensity present     yes/no 
 
Mass effect       yes/no, if yes each yes/no 
• Succal effacement 
• Ventricular effacement 
• Midline shift 
• Uncal herniation 
 
1/3 MCA territory      yes/no 
 
ASPECT score, for each region    yes/no 
 
Second discrete lesion     yes/no 
 
Hyperdense artery      yes/no, if yes then site 
 
2.9.5 Haemorrhage 
 
By presence, importance and size (<3, 3-5, 5-8, >8 cm): 
• Petechial 
• Haemorrhagic transformation of infarct 
• Parenchymal haematoma (no infarct) 
• Parenchymal haematoma (remote from infarct) 
• Subdural haematoma 
• Subarachnoid haemorrhage 
• Extradural haemorrhage 
 
2.9.6 Other features 
 
Reduction in brain tissue volume: none, moderate severe: 
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• Central 
• Cortical 
 
Periventricular lucencies: none, restricted to region adjoining ventricles, from ventricle to 
cortex 
• Anterior white matter 
• Posterior white matter 
 
Old vascular lesions: each yes/no 
• Cortical infarct(s) 
• Striatocapsular infarct(s) 
• Borderzone infarct(s) 
• Lacunar infarct(s) 
• Brainstem/cerebellar infarct(s) 
 
Non-stroke lesions, each yes/no 
• Cerebral tumour 
• Encephalitis 
• Cerebral abscess 
• Other, e.g. contusion 
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APPENDIX C. TABLES AND FIGURES IN PRIMARY PUBLICATIONS 
 
Authors 
ENOS Trial Investigators 
 
Format 
The primary publications for the GTN vs no GTN, and continue vs stop pre-stroke 
antihypertensive medications will share the same format for tables and figures as 
highlighted below. Any additions to, or differences in, one or other publication are given 
separately. 
 
1 Table 1. Baseline characteristics 
 
1.1 Both GTN/no GTN and Continue/Stop publications 
 
Table 1. Baseline characteristics of patients enrolled into the ENOS trial. Data are 
number (%), median [interquartile range] or mean (standard deviation). 
  
 All patients GTN No GTN 
 All patients Continue Stop 
Number of patients    
Age (years) †    
Sex, male (%) †    
Geographical region ‡    
   Africa    
   America, north    
   Asia, east    
   Asia, south    
   Asia, south-east    
   Australasia    
   British Isles    
   Europe, mainland    
Pre-stroke mRS [/6]    
Medical history (%)    
   Treated hypertension ‡    
   Atrial fibrillation, current/previous    
   Stroke    
   Ischaemic heart disease    
   Peripheral arterial disease    
   Smoking, current (%)    
Qualifying event (%) †    
   Ischaemic stroke    
   Spontaneous intracerebral haemorrhage    
   Stroke type unknown    
   Non-stroke    
Side of lesion, right (%)    
Scandinavian Stroke Scale (/58) †    
   NIHSS (/42), calculated 40    
Glasgow Coma Scale [/15]    
OCSP classification (%)    
   Total anterior †    
   Partial anterior    
   Lacunar    
   Posterior    
TOAST classification (%) Ω∫    
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   Cardioembolic    
   Large vessel    
   Small vessel    
   Mixed    
   Other    
Haemodynamics    
   Systolic blood pressure (mmHg) †    
   Diastolic blood pressure (mmHg)    
   Heart rate, mean (bpm)    
Oral feeding (%)    
Time onset to randomisation (hours) †    
Thrombolysis †    
† Minimisation variable; ‡ Stratification variable; Ω Ischaemic patients only; ∆ Protocol 
violation 
bpm: beats per minute; NIHSS: National Institutes of Health Stroke Scale; mRS: 
modified Rankin Scale; OCSP: Oxford Community Stroke Project TOAST: Trial of ORG 
10172 in Acute Stroke Treatment 
 
 
1.2 Continue vs stop pre-stroke antihypertensive medications 
 
The following variables will also be given in table 1 of this primary paper. 
 
 All patients Continue Stop 
Number of patients    
…    
Medications (%)    
   Blood pressure lowering    
      Angiotensin converting enzyme inhibitor    
      Angiotensin receptor antagonist    
      Renin inhibitor    
      ß-receptor antagonist    
      Calcium channel blocker    
      Diuretic    
      α-receptor antagonist    
      Centrally acting    
      Other    
   Blood pressure, number taken, median    
      0 (%) ∆    
      1 (%)    
      2 (%)    
      3 (%)    
      4 (%)    
      5 (%)    
      6 (%)    
…       
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2. Table 2. Compliance 
 
2.1 Both GTN/no GTN and Continue/Stop publications 
 
Table 2. Compliance and reasons for non-compliance from randomised treatment. 
Patients receiving at least first 4 doses are considered to have had full treatment. Data 
are number (%) Comparison of total withdrawals by binary logistic regression with 95% 
confidence intervals. 
 
Reasons for non-compliance All GTN No GTN 
Reasons for non-compliance All Continue Stop 
Participants randomised    
Compliance    
   Received all 7 days of treatment    
   Received first 4 days of treatment    
   Received first treatment    
   Did not receive any randomised treatment    
Non-compliance by day 4 (%)    
   Discharged    
   Physician withdrew participant    
   Adverse event, unacceptable    
      Headache    
   Serious adverse event    
   Consent withdrawal by participant or relative    
   Death    
   Other    
 
Odds ratio= , 95% confidence interval = - , 2p= . 
Note: Patients who were randomised to GTN and were discharged before day 7 were 
given their remaining GTN patches to take in the community 
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3 Table 3. Outcomes 
 
3.1 Both GTN/no GTN and Continue/Stop publications 
 
Table 3. Primary and secondary outcomes at 7 and 90 days. Data are number (%), 
median [interquartile quartile range] or mean (standard deviation). Comparison by 
binary logistic regression, ordinal logistic regression, or multiple linear regression, shown 
as odds ratio (OR) median [interquartile range] or mean difference (MD), with 95% 
confidence intervals. Analyses are adjusted unless stated. 
 
Outcome GTN No 
GTN 
OR/MD (95% CI), 
adjusted 
2p 
 
Outcome Continue Stop OR/MD (95% CI), 
adjusted 
2p 
 
Primary outcome     
Modified Rankin Scale (/6)   OR  
     
Sensitivity analyses     
   mRS (/6), adjusted plus geographical 
region 
    
   mRS (/6), unadjusted     
   mRS>2     
   mRS>2, unadjusted     
   Global outcome - -   
     
Secondary outcomes     
Day 7 (or discharge)     
Death, by cause (%)     
   Stroke progression   -  
   Recurrent stroke   -  
   Intra-cranial bleeding   -  
   Extra-cranial bleeding   -  
   Myocardial infarction    -  
   Other cardiovascular cause   -  
   Pulmonary embolism   -  
   Pneumonia   -  
   Other sudden death   -  
   Other cause   -  
   Other infection   -  
Symptomatic intracranial haemorrhage 
(%) 
    
Major extracranial haemorrhage (%)     
Symptomatic recurrent stroke, all (%)     
   Ischaemic   -  
   Haemorrhage   -  
   Unknown   -  
Scandinavian Stroke Scale (SSS, /58) ‡     
   NIH Stroke Scale (/42), calculated 40     
Clinical deterioration (%) †     
Neurological deterioration (%)     
Headache (%)     
Hypotension (%)     
Hypertension (%)     
Venous thromboembolism (%)     
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Hospital events     
Hospital stay (days)     
Discharged home (%)     
     
Day 90     
Death (%)     
Barthel Index (BI, /100) ‡     
Barthel Index <60 (%)     
Zung Depression Scale (ZDS, /100) ‡     
EQ-5D Health Utility Status (HUS, /1) ‡     
EQ-Visual Analogue Scale (EQ-VAS, 
/100) ‡ 
    
 
† Neurological deterioration: decrease in SSS >4 points and/or decrease in 
consciousness on SSS >2 points; ‡: Death assigned, SSS -1, BI -5, ZDS 102.5, HUS 0, 
VAS -1 
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4 Table 4. Serious adverse events 
 
4.1 Both GTN/no GTN and Continue/Stop publications 
 
Table 4. Serious adverse events up to day 90. Data are number (%) of affected patients. 
Comparison by binary logistic regression. 
 
Number (%) Median time 
to event 
(days) 
All   Fatal   
Cause  GTN No 
GTN 
2p GTN No 
GTN 
2p 
Cause  Continue Stop 2p Continue Stop 2p 
Neurological        
   Complication of initial 
stroke 
       
   Extension of initial 
stroke 
       
   Haemorrhagic 
transformation of infarct 
       
   Intracerebral bleed        
   Recurrent stroke        
Cardiac        
   Cardiac failure        
   Hypertension        
   Hypotension        
   Myocardial infarction         
   Sudden cardiac death  - - -    
Gastrointestinal        
   Bleed        
   Infarction        
Respiratory        
   Pneumonia        
   Pulmonary embolism        
Other        
   Death, unattended  - - -    
   Extracranial bleeding        
   Malignancy/cancer        
   Septicaemia        
   Urinary tract infection        
   Renal impairment        
   Electrolyte imbalance        
 
 
4.2 Continue vs stop pre-stroke antihypertensive medications 
 
Table 4a. Specific serious adverse events up to day 90 by antihypertensive drug class 
(where >15% of patients were taking the class) and by number of drug classes (where 
>15% of patients were taking that number of drugs). Data are number (%) of affected 
patients; the percentage of affected patients across drug classes may exceed 100%. 
Comparison by binary logistic regression. 
 
Number (%) Median time to 
event (days) 
All   Fatal   
Cause  Continue Stop 2p Continue Stop 2p 
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Drug class        
   ACE-I or ARB        
   ß-receptor 
antagonist 
       
   Calcium channel 
blocker 
       
   Diuretic        
   Other BP classes 
† 
       
Number of drugs 
(%) 
       
   1        
   2        
   3        
   4         
   >4        
† Other BP classes: alpha-receptor antagonist, centrally acting drugs, renin inhibitor  
Index stroke-related: 
Any of: complication of initial stroke, extension of initial stroke, recurrent stroke, 
haemorrhagic transformation of stroke; intracerebral bleed, recurrent stroke. 
If the analysis shows a treatment-related stroke, the comparison will then be performed 
for each of these components.  
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5 Table 5. Protocol violations 
 
5.1 Both GTN/no GTN and Continue/Stop publications 
 
Table 5. Protocol violations by treatment group. Data are number (%). 
 
 GTN No GTN 
 Continue Stop 
Inclusion criteria   
   Failure to obtain consent/assent   
   Age <18 years   
   Time >48 hours   
   GCS <8 (/15)   
   No limb weakness   
   No SBP <220 or >140 mmHg   
   Known non-stroke intracranial pathology   
   No brain imaging or autopsy   
Treatment   
   Received antihypertensive drug(s) prior to randomisation   
 
 
In addition, for GTN vs no GTN 
 
 Continue Stop 
Treatment   
   Failure to stop pre-stroke nitrate treatment   
   Failure to receive GTN for >4 days if randomised to GTN   
   Received any GTN during first 4 days if randomised to no GTN   
 
 
In addition, for continue versus stop pre-stroke antihypertensive drugs 
 
 Continue Stop 
Inclusion criteria   
   Enrolled but not on a pre-stroke antihypertensive agent   
Treatment   
   Received usual antihypertensive drug(s) before randomisation   
   Received usual or new antihypertensive drug(s) when randomised to 
stop 
  
   Failure to receive pre-stroke antihypertensive drug(s) when 
randomised to continue 
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6 Table A. Blood pressure 
 
6.1 Both GTN/no GTN and Continue/Stop publications 
 
Table A. Blood pressure, systolic/diastolic (mmHg) course over 7 days of treatment. 
Data are mean (standard deviation) [number]. Comparison by t test with adjustment for 
multiple comparisons using Bonferroni correction. 
 
Day GTN No GTN Difference 
(SBP/DBP) 
2p 
Day Continue Stop Difference 
(SBP/DBP) 
2p 
0, baseline   - - 
1, 2 hours post patch     
2     
3     
4     
5     
6     
7     
 
Note: PLAN IS TO SHOW THIS AS A FIGURE BUT NUMBERS NEEDED IN FIRST INSTANCE 
 
 
 
7 Table B. mRS by treatment assignment 
 
7.1 Both GTN/no GTN and Continue/Stop publications 
 
mRS 0 1 2 3 4 5 Death 
GTN N1 (%) . . . . . . 
No GTN . . . . . . . 
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8 Table C. Outcome by sub-groups 
 
8.1 Both GTN/no GTN and Continue/Stop publications 
 
Effect of GTN vs no GTN on mRS at day 90 in subgroups defined at baseline. Data are 
odds ratio (95% confidence intervals) and interaction test. Comparison by ordinal logistic 
regression. 
 
Variable GTN No GTN OR 
(95% CI) 
Interaction p 
Variable Continue Stop OR 
(95% CI) 
Interaction p 
Age, <70     
Age, >70    - 
Sex, female     
Sex, male    - 
History of hypertension, no     
History of hypertension, yes    - 
Stroke, ischaemic     
Stroke, ICH    - 
Stroke syndrome, LACS     
Stroke syndrome, PACS    - 
Stroke syndrome, POCS    - 
Stroke syndrome, TACS    - 
Stroke severity, SSS >40     
Stroke severity, SSS 30-40    - 
Stroke severity, SSS <30    - 
Systolic BP, <160     
Systolic BP, 161-180    - 
Systolic BP, 181-200    - 
Systolic BP, >200    - 
AF, absent     
AF, present    - 
Feeding, oral     
Feeding, not oral    - 
Ipsilateral carotid stenosis, 0-49%     
Ipsilateral carotid stenosis, 50-69%    - 
Ipsilateral carotid stenosis, 70-99%    - 
Ipsilateral carotid stenosis, 100%    - 
Time to randomisation, <6 hr     
Time to randomisation, 6.1-12    - 
Time to randomisation, 12.1-24    - 
Time to randomisation, 24.1-36    - 
Time to randomisation, >36    - 
Treatment, alteplase     
Treatment, no alteplase    - 
All patients      
 
 
GTN vs no GTN paper 
 
Variable GTN No GTN OR 
(95% CI) 
Interaction p 
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History of recent nitrate, no     
History of recent nitrate, yes    - 
Pre-stroke BP medication, not relevant     
Pre-stroke BP medication, continue     
Pre-stroke BP medication, stop     
 
 
Continue vs stop pre-stroke BP medications paper 
 
Variable Continue Stop OR 
(95% CI) 
Interaction p 
BP class, ACE-I/ARA/RI     
BP class, ß-RA    - 
BP class, CCB     
BP class, diuretic     
BP class, centrally acting     
BP class, other     
No. of BP drugs, 1     
No. of BP drugs, 2     
No. of BP drugs, 3     
No. of BP drugs, 4     
No. of BP drugs, >4     
Randomised to GTN     
Randomised to no GTN     
 
NOTE: These tables will be presented as a Forest plot. 
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9 Figure 1. Trial flow diagram 
 
9.1 Both GTN/no GTN and Continue/Stop publications 
 
Figure 1. CONSORT flow diagram of patient randomisation, outcome, and losses to 
follow-up. Screening for eligibility was not collected routinely. Data are number (%). 
 
Randomised    
 í  î 
Treatment allocation GTN  No GTN 
Treatment allocation Continue  Stop 
Number allocated (safety population)    
Baseline data completed    
Adherence to allocation ê  ê 
   Any GTN or no GTN (efficacy population)    
   First dose of GTN or no GTN     
   > 4days of GTN or no GTN (s)    
   All 7 days of GTN or no GTN    
Day 7 follow-up (end of treatment) ê  ê 
   Death by day 7    
   Day 7 assessment completed    
      <4 days    
      7-10 days (per protocol)    
      >10 days    
   Day 7 assessment missing    
      Patient refused    
      Logistical problem    
      Other reason    
Hospital discharge or death ê  ê 
   Death in hospital    
   Hospital event form completed    
      Before day 90 follow-up    
      On day 90 follow-up    
   Hospital event form missing    
      Patient refused    
      Logistical problem    
      Other reason    
Day 90 follow-up (end of follow-up) ê  ê 
   Death by day 90    
      No vital status available    
   Day 90 assessment completed    
      <83 days    
      83-97 days (per protocol)    
      >97 days    
   Day 90 mRS assessment missing    
      Patient lost to follow-up    
      Patient refused    
      Logistical problem    
      Other    
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10 Figure 2. Blood pressure profile 
 
10.1 Both GTN/no GTN and Continue/Stop publications 
 
Figure 2. Blood pressure during 7 days of treatment. ΔSBP and ΔDBP signify mean 
difference in systolic and diastolic blood pressure between the two groups; p values were 
calculated with the independent sample t test, and are for difference in systolic blood 
pressure between groups. 
 
See table A for source data. 
 
 
 
11 Figure 3. Modified Rankin Scale distribution 
 
11.1 Both GTN/no GTN and Continue/Stop publications 
 
Figure 3. Modified Rankin Scale (mRS) at 90 days follow-up. Distribution of mRS scores 
by treatment group. Comparison by ordinal logistic regression adjusted for baseline 
factors. 
 
See table B for source data. 
 
 
 
12 Figure 4. Primary outcome in pre-specified subgroups 
 
12.1 Both GTN/no GTN and Continue/Stop publications 
 
Figure 4. Subgroup analysis of effects on functional outcome at 90 days. Pre-defined 
subgroups are listed in section 4.4.3. 
 
See table C for source data. 
 
 
 
13 Figure 5. Survival curve 
 
13.1 Both GTN/no GTN and Continue/Stop publications 
 
Figure 5. Cumulative hazard of death during the 90 days of follow-up after 
randomisation. Cox proportional regression with adjustment for baseline covariates, 
hazard ratio= (95% CI - ), p= . 
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14 Figure 6. Meta-analysis of relevant trials 
 
14.1 GTN/no 
 
Figure 6. Meta-analysis of trials in acute stroke involving drugs which lower blood pressure and which included more than 100 
patients: effect on death or dependency 
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14.2 Continue/stop 
 
Figure 6. Meta-analysis of trials in acute stroke comparing continuing versus stopping pre-stroke antihypertensive drugs and which 
included more than 100 patients: effect on death or dependency 
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APPENDIX D. SECONDARY PUBLICATIONS 
 
1 PUBLISHED 
 
a. Protocol 15 
b. The NeuroGrid stroke exemplar clinical trial protocol 41 
c. Efficacy of Nitric Oxide in Stroke – a randomized trial. Characteristics of patients 
recruited in Poland16 
d. The Efficacy of Nitric Oxide in Stroke (ENOS) trial – where do we stand in 
Romania? 20 
e. Safety and efficacy of lowering BP in patients with severe carotid stenosis 42 
f. Effect of the neutral CLOTS-1 trial on the use of graduated compression stockings 
in the Efficacy of Nitric Oxide Stroke (ENOS) trial 18 
g. Testing for differential item functioning within the EQ-5D 19 
h. Comparison of small volume infarcts of lacunar and non-lacunar aetiologies 43 
 
 
2 SUBMITTED 
 
a. Relationship between cognitive impairment after stroke, baseline factors and 
functional outcome: Data from ENOS trial 
b. Very low quality of life after acute stroke: data from the Efficacy of Nitric Oxide in 
Stroke (ENOS) trial. Stroke 
 
 
3 IN PREPARATION 
 
a. Methods for quantifying and qualifying intracerebral haemorrhage 
b. Baseline characteristics. (To be submitted once last patient recruited. Appendix E) 
 
 
4 PLANNED PUBLICATIONS 
 
4.1 Treatment-related 
a. The nitric oxide donor glyceryl trinitrate for treatment of acute stroke: the Efficacy 
of Nitric Oxide in Stroke (ENOS) randomised controlled trial (ISRCTN99414122). 
(Primary publication. Appendix C) 
b. Continuing versus temporary stopping of pre-stroke antihypertensive therapy in 
patients with in acute stroke: the Efficacy of Nitric Oxide in Stroke (ENOS) 
randomised controlled trial (ISRCTN99414122). (Primary publication. Appendix C) 
c. Glyceryl trinitrate and/or continuing pre-stroke antihypertensive medications in 
acute ischaemic stroke. (Appendix F) 
d. Glyceryl trinitrate and/or continuing pre-stroke antihypertensive medications in 
acute spontaneous intracerebral haemorrhage. (Appendix G) 
e. Glyceryl trinitrate for reducing cognition, quality of life and mood after stroke 
f. Continuing versus stopping pre-stroke antihypertensive medication for reducing 
cognition, quality of life and mood after stroke 
g. GTN-no GTN/Continue-stop and scan outcome at day 7 (Appendix E) 
h. GTN, headache and outcome (Appendix F) 
i. Effect of GTN on dysphagia (Appendix H) 
j. Relationship between treatment-related change in blood pressure and outcome (as 
in SCAST 44) 
k. Effect of GTN on haemodynamic parameters: systolic and diastolic BP, heart rate, 
pulse pressure, peak BP, BP variability, rate-pressure product and their 
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relationship to outcome (as in 45) 
l. Health economics of GTN vs no GTN and/or Continue vs stop (if positive primary 
outcome) 
 
4.2 ‘Epidemiological’ (not treatment-related) 
a. Comparison of functional outcomes between countries (as in 46-48) 
b. Outcomes in UK 
c. Identification of baseline phenotypic factors that predict cognitive outcomes 
 
4.3 Systematic reviews/meta-analyses 
a. Temporal effects of GTN on outcome, a meta-analysis of individual patient data 
from randomised controlled trials of GTN (Appendix M) 
b. Comparison of continuing or temporary stopping pre-stroke antihypertensive 
medication: a prospective meta-analysis of individual patient data from 
randomised controlled trials (Appendix N). (A draft paper, based on merging data 
from ENOS, COSSACS,49 and any other relevant trial(s), was written prior to the 
unblinding of COSSACS.) 
c. Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors in 
acute ischaemic stroke.50 Update of this Cochrane Database of Systematic Review 
d. Vasoactive drugs for acute stroke.51 Update of this Cochrane Database of 
Systematic Review 
e. Interventions for deliberately altering blood pressure in acute stroke.52 Update of 
this Cochrane Database of Systematic Review 
f. Blood pressure in Acute Stroke Collaboration: Intracerebral haemorrhage 
g. Blood pressure in Acute Stroke Collaboration: Ischaemic stroke 
h. Blood pressure in Acute Stroke Collaboration: All stroke 
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APPENDIX E. PLANNED PUBLICATION: BASELINE DATA 
 
Authorship 
To be decided. 
 
Title 
Characterisation of patients enrolled into the ‘Efficacy of Nitric Oxide’ in Stroke 
(ENOS) trial. 
 
Authors 
Members of Trial Steering Committee, International Advisory Committee and Trial 
Management Committee. 
 
Aim 
To characterise the patients enrolled into ENOS. For submission after enrolment of the 
last patient in quarter 4 2013. 
 
Patients 
All randomised patients. 
 
Table 1 
Recruitment: number of sites and patients by country 
 
Country No. of sites No. of patients % 
Australia    
Canada    
China    
Denmark    
Egypt    
Eire    
Georgia    
Greece    
Hong Kong    
India    
Italy    
Malaysia    
Norway    
New Zealand    
Philippines    
Poland 16    
Romania 20    
Singapore 43    
Sri Lanka    
Spain    
Sweden    
Turkey    
UK    
TOTAL   100 
 
 
Table 2. 
Clinical characteristics at baseline. Data are number (%), median [interquartile range] 
or mean (standard deviation). 
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 All 
patients 
Continue-
stop 
Not in 
continue-stop 
No. of patients    
Age (years)    
   <18 (%) ¶    
   18-40 (%)    
   41-50 (%)    
   51-60 (%)    
   61-70 (%)    
   71-80 (%)    
   81-90 (%)    
   91-100 (%)    
   >100 (%)    
   Mean (SD) †    
Sex    
   Male (%) †    
   Female (%)    
Geographical region ‡    
   Africa    
   America, north    
   Asia, east    
   Asia, south    
   Asia, south-east    
   Australasia    
   British Isles    
   Europe, mainland    
Medical history (%)    
   Hypertension    
   Treated hypertension ‡    
   Hyperlipidaemia    
   Diabetes mellitus    
   Atrial fibrillation, current/previous    
   Stroke    
   Transient ischaemic attack    
   Ischaemic heart disease    
   Peripheral arterial disease    
   Family history of young stroke, first 
degree relative 
   
   Smoking (%)    
      Current    
      Past    
      Never    
   Alcohol, median [upw]    
      >21 units per week    
      <21    
      None    
Pre-morbid modified Rankin Scale [/2]    
   mRS 0    
   mRS 1    
   mRS 2    
   mRS>2 ¶    
Medications (%)    
   Blood pressure lowering    
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      Angiotensin converting enzyme 
inhibitor 
   
      Angiotensin receptor antagonist    
      Renin inhibitor    
      ß-receptor antagonist    
      Calcium channel blocker    
      Diuretic    
      α-receptor antagonist    
      Centrally acting    
      Other    
   Blood pressure tablets, number taken    
      Mean (SD)    
      Median [IQR]    
      Mode    
      0 (%)    
      1 (%)    
      2 (%)    
      3 (%)    
      4 (%)    
      >4 (%)    
   Lipid lowering    
   Nitrate    
Side of lesion, right (%)    
Scandinavian Stroke Scale (/58)    
   Mean (SD) †    
   Median [IQR]    
   51-58    
   41-50    
   31-40    
   21-30    
   11-20    
   0-10    
   NIHSS (/42), calculated 40    
Glasgow Coma Scale [/15]    
   15    
   14    
   13    
   12    
   11    
   10    
     9    
   <9 ¶    
OCSP classification (%)    
   Total anterior †    
   Partial anterior    
   Lacunar    
   Posterior    
TOAST classification (%) Ω∫    
   Cardioembolic    
   Large vessel    
   Small vessel/lacunar    
   Mixed    
   Unknown    
Haemodynamics    
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† Minimisation variable; ‡ Stratification variable; Ω Ischaemic only; ∫ May exceed 
100%; ¶ Protocol violation 
bpm: beats per minute; NIHSS: National Institutes of Health Stroke Scale; TOAST: 
Trial of ORG 10172 in Acute Stroke Treatment 
 
 
  
   Systolic blood pressure (mmHg)     
      <140 (mmHg)    
      140-160 (mmHg)    
      161-180 (mmHg)    
      181-200 (mmHg)    
      201-220 (mmHg)    
      >220 (mmHg)    
      Mean (SD) †    
   Diastolic blood pressure, mean (mmHg)    
   Heart rate, mean (bpm)    
Temperature (oC)    
Glucose (mmol/l)    
Feeding (%)    
   Normal diet    
   Soft diet    
   Nasogastric fed    
   PEG-fed    
   Intravenous/subcutaneous fluids    
   Nil    
Time stroke-randomisation (hours)    
   <1 (%) ¶    
   1-6 (%)    
   7-12 (%)    
   13-18 (%)    
   19-24 (%)    
   25-36 (%)    
   37-48 (%)    
   >48 (%) ¶    
   Median [IQR]    
   Mean (SD) †    
Thrombolysis, given †    
Qualifying event, by investigator (%) †    
   Ischaemic    
      Ischaemic stroke, no lesion on brain 
scan 
   
      Ischaemic stroke, lesion on brain scan    
      Haemorrhagic transformation of 
infarct 
   
      Not known    
   Intracerebral haemorrhage    
   Stroke type unknown    
   Non-stroke    
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Table 3. Issues with the trial. 
 
Issue Explanation Effect/Response 
Sponsorship Insurance and contracting issues 
prevented a number of countries from 
participating in ENOS. 
Reduced world coverage 
and recruitment. 
Recruitment, 
rate low 
Recruitment limited by: Severe acute 
respiratory syndrome (SARS), Bird flu, 
competing trials, trial fatigue. 
Delayed recruitment at 
various sites, especially 
in Singapore. 
Recruitment, 
rate too high 
Two sites over-recruited: 
Site A: Outcome was poorly recorded, 
and had several losses to follow-up. A 
limited number of scans were available. 
Site B: Review of baseline and follow-up 
data, consent forms, treatment charts 
and brain scans revealed no problem. 
A: Site closed. 
B: No action. 
Recruitment, 
delayed 
Tendency for patients to be recruited 
during day 2, in spite of repeated 
requests to investigators to focus on 
recruiting patients at the time of 
presentation to hospital. 
Extended mean time to 
recruitment. 
Randomisation 
to continue/stop 
Patients not on pre-stroke 
antihypertensive drugs randomised in 
error (N= ). 
Sites training on 
inclusion criteria 
Non-
randomisation to 
continue/stop 
Patients on pre-stroke antihypertensive 
drugs not randomised because drug(s) 
not recognised as an antihypertensive 
(N= ). 
Sites given full 
international list of anti-
hypertensive agents. 
Non-availability 
of placebo GTN 
patches 
Placebo patches were made available by 
one manufacturer for the first pilot 
trial.10 Pilot trials 2-4 used a single-blind 
design with GTN patch (or similar area 
of skin) covered by a gauze dressing.11-
13 
ENOS designed as 
single-blind study as for 
pilot trials 2-4. 
Loss of 
availability of 
GTN patches 
In China, GTN patches were sourced 
from a local manufacturer. A reduction 
in the national reimbursement for 
manufacturing these patches meant 
that the company ceased their 
production. Importation of patches from 
overseas probed too complicated to 
organise. 
Cessation of recruitment 
in China. 
Inappropriate 
GTN treatment 
GTN given open-label to all   patients at 
one site irrespective of randomisation. 
Data from this site 
excluded from all 
analyses (exclusion in 
2012, i.e. prior to data 
lock). 
Theft of data Theft of paper case report forms and 
brain scan films from one site relating 
to   patients. 
Missing follow-up and CT 
scan data. 
Withdrawals Withdrawal from follow-up (N= ) or lost 
to follow-up (N= ). 
Missing primary outcome 
data. 
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Table 4. Univariate correlations between baseline characteristics for: age, 
sex, stroke severity (Scandinavian Stroke Scale, SSS), stroke pathological 
type (ischaemic, haemorrhage), systolic blood pressure (SBP), time to 
randomisation, and year of randomisation. Correlations by point biserial or 
Spearman’s tests; data are regression coefficient and p value. 
 
 Age Sex, 
male 
Severity 
(SSS) 
Stroke 
type, 
bleed 
Systolic 
BP 
Time to 
randomisation 
Year of 
randomisation 
Age X       
Sex  X      
Severity   X     
Type    X    
SBP     X   
Time      X  
Year       X 
 
 
 
Figure 1. Recruitment curve throughout the trial. 
 
 
 
Figure 2. Scatterplots and box and whisker plots showing univariate-
relationships between baseline variables 
Scatterplots and box-and-whisker plots of (i) age versus stroke severity (Scandinavian 
Stroke Scale, SSS); (ii) age vs systolic blood pressure (SBP); (iii) SSS vs SBP; (iv) 
Time stroke-randomisation vs SBP; (v) Time stroke-randomisation vs SSS. 
 
 
APPENDIX A. ENOS protocol version 1.5 – latest/current version 
 
 
 
APPENDIX B. ENOS protocol version 1.5 - signed front page. 
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APPENDIX F. PLANNED PUBLICATION: GLYCERYL TRINITRATE AND/OR 
CONTINUING PRE-STROKE ANTIHYPERTENSIVE MEDICATIONS IN ACUTE 
ISCHAEMIC STROKE 
 
Authorship 
Kailash Krishnan, …, Rob Dineen, Joanna Wardlaw, Philip Bath 
 
Title 
Glyceryl trinitrate and/or continuing pre-stroke antihypertensive medications in acute 
ischaemic stroke. 
 
Authors 
To include neuroimaging adjudicators. 
 
Aim 
To assess the effect of GTN vs no GTN, and continue vs stop temporarily pre-stroke 
antihypertensive medications, in patients with a final diagnosis of acute ischaemic 
stroke. 
 
Patients 
All randomised patients with acute ischaemic stroke, by intention-to-treat. 
 
Layout 
The publication will follow the format of the two primary publications (baseline 
characteristics, BP profile, clinical outcomes, SAEs, mRS distribution, survival) but will 
report the effect of both intervention comparisons (GTN vs no GTN, continue vs stop 
pre-stroke antihypertensive agents) in patients with acute ischaemic stroke as the 
final diagnosis. In addition, adjudicated information on baseline imaging data will be 
described (reporting the imaging variables in the table below), as will the effect of the 
interventions on day 7 imaging parameters (adjusted for baseline) where available 
(table). 
 
Imaging data 
The effect of the interventions on imaging parameters will be assessed where both 
baseline and day 7 data are present. The method of analysis is given for each imaging 
parameter. 
 
Table 1. Baseline IS characteristics 
Baseline demographic, clinical and neuroimaging characteristics of patients with acute 
ischaemic stroke. Data are number (%), median [interquartile range] or mean 
(standard deviation). 
 
 All GTN No 
GTN 
Continue Stop 
Patients (N)      
Country, UK (%)      
Age (years)      
Sex, male (%)      
Smoking, current (%)      
Pre-morbid mRS =0 (%)      
Previous stroke (%)      
Prior antihypertensive drug use (%)      
Prior history of high BP (%)      
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Diabetes mellitus (%)      
Ischaemic heart disease (%)      
Atrial fibrillation (%)      
TACS (%)      
Scandinavian Stroke Scale (/58)      
Glasgow Coma Scale [/15]      
Systolic blood pressure (mmHg)      
Diastolic blood pressure (mmHg)      
Heart rate (bpm)      
Onset to neuroimaging (%)      
   <12 hours      
   12-24 hours      
    >24 hours      
Location of infarct (%)      
   Lobar      
   Basal ganglia or thalamus      
   Brainstem      
   Cerebellum      
   Undetermined      
Site      
Lesion size: MCA, lacunar, cerebellum or 
brainstem 
     
Mass effect, degree      
Haemorrhagic Transformation of Infarct      
Loss of grey-white definition      
Loss of basal ganglia outline      
Hypodensity      
Hypoattenuation      
Mass effect      
Mass effect score (greatest of Uncal> shift> 
ventricular> sulcal) 
     
Middle Cerebral Artery 1/3 (if MCA, >1/3, <1/3, 
no lesion) 
     
ASPECTS score      
Second lesion      
Hyperdense artery      
Leukoaraiosis      
Previous stroke lesion (%)      
 
bpm: beats per minute 
 
 
Table 2. Effect of interventions on imaging outcomes at day 7 
Effect of GTN vs no GTN, and continue vs stop temporarily pre-stroke 
antihypertensive agents, on imaging outcomes at day 7. Data are number (%), 
median (interquartile range) or mode. Comparisons by binary logistic regression or 
ordinal logistic regression, with adjustment for age; sex; history of hypertension; 
previous stroke; diabetes mellitus; current use of nitrate therapy (not for continue vs 
stop); stroke severity (SSS); total anterior circulation syndrome; systolic BP; treated 
with rt-PA prior to randomisation; feeding status; and time from onset to 
randomisation. 
 
Imaging parameter GTN No OR p Continue Stop OR p 
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Table 3. Effect of interventions on clinical outcomes 
Effect of GTN vs no GTN, and continue vs stop temporarily pre-stroke 
antihypertensive agents, on clinical outcomes. Data are number (%), median 
(interquartile range) or mean (standard deviation). Comparisons by binary logistic 
regression, ordinal logistic regression or multiple linear regression, with adjustment 
for age; sex; history of hypertension; previous stroke; diabetes mellitus; current use 
of nitrate therapy (not for continue vs stop); stroke severity (SSS); total anterior 
circulation syndrome; systolic BP; alteplase; and time from onset to randomisation. 
 
 All GTN No GTN OR/ß Continue Stop OR/ß 
Day 7        
Patients (N)        
Death (%)        
Death or deterioration (%)        
SSS (/58)        
Recurrence (%)        
SBP (mmHg)        
        
Hospital events        
Patients (N)        
Death (%)        
Length of stay (days)        
Home (%)        
        
Day 90        
Patients (N)        
Death (%)        
Modified Rankin Scale (/6)        
GTN 
Patients (N)         
Recent stroke         
Site         
Lesion size: MCA, lacunar, cerebellum 
or brainstem 
        
Mass effect, degree         
Haemorrhagic transformation of infarct         
Loss of grey-white definition         
Loss of basal ganglia outline         
Hypodensity         
Hypoattenuation         
Mass effect         
Mass effect score (greatest of Uncal> 
shift> ventricular> sulcal) 
        
Middle cerebral artery 1/3 (if MCA, 
>1/3, <1/3, no lesion) 
        
ASPECTS score         
Second lesion         
Hyperdense artery         
PVL         
Atrophy         
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Barthel Index (/100)        
tMMSE (/16)        
TICS (/39)        
Animal naming (/∞)        
ZDS (/100)        
HUS (EQ-5D) (/1)        
EQ-VAS (/100)        
 
 
Figure 1. Death by treatment group 
Forest plot for hazard of death (calculated by Cox regression) with 95% confidence 
intervals at day 90 by pre-specified baseline covariates (as listed in section 4.4.3) for 
(a) GTN vs no GTN; and (b) continue vs stop pre-stroke antihypertensive medications. 
 
 
Figure 2. Functional outcome by treatment group 
Forest plot for odds ratio of mRS (calculated by ordinal logistic regression) with 95% 
confidence intervals at day 90 by pre-specified baseline covariates (as listed in section 
4.4.3) for (a) GTN/no GTN; and (b) continue/stop pre-stroke antihypertensive 
medications. 
 
 
Figure 3. Survival by treatment group 
Kaplan-Meier plot for survival for (a) GTN/no GTN; and (b) continue/stop pre-stroke 
antihypertensive medications. 
 
 
Figure 4. Functional outcome by treatment group in imaging subgroups 
Forest plot for odds ratio of mRS (calculated by ordinal logistic regression) with 95% 
confidence intervals at day 90 for GTN/no GTN by pre-specified baseline imaging 
covariates: large lesion, hyperdense artery, atrophy, old lesions, WML 
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APPENDIX G. PLANNED PUBLICATION: GLYCERYL TRINITRATE AND/OR 
CONTINUING PRE-STROKE ANTIHYPERTENSIVE MEDICATIONS IN ACUTE 
SPONTANEOUS INTRACEREBRAL HAEMORRHAGE 
 
Authorship 
Kailash Krishnan, …, Rob Dineen, Niki Sprigg, Joanna Wardlaw, Philip Bath 
 
Title 
Glyceryl trinitrate and/or continuing pre-stroke antihypertensive medications in acute 
spontaneous intracerebral haemorrhage. 
 
Authors 
To include neuroimaging adjudicators and K Krishnan. 
 
Aim 
To assess the effect of GTN vs no GTN, and continue vs stop temporarily pre-stroke 
antihypertensive medications, in patients with a final diagnosis of acute spontaneous 
intracerebral haemorrhage. 
 
Patients 
All randomised patients with acute spontaneous intracerebral haemorrhage, by 
intention-to-treat. 
 
Layout 
The publication will follow the format of the two primary publications (baseline 
characteristics, BP profile, clinical outcomes, SAEs, mRS distribution, survival) but will 
report the effect of both intervention comparisons (GTN vs no GTN, continue vs stop 
pre-stroke antihypertensive agents) in patients with acute spontaneous intracerebral 
haemorrhage as the final diagnosis. In addition, adjudicated information on baseline 
imaging data will be described (reporting the imaging variables in the table below), as 
will the effect of the interventions on day 7 imaging parameters (adjusted for 
baseline) where available (table). 
 
Imaging data 
The effect of the interventions on imaging parameters will be assessed where both 
baseline and day 7 data are present. The method of analysis is given for each imaging 
parameter. 
 
Table 1. Baseline ICH characteristics 
Baseline demographic, clinical and neuroimaging characteristics of patients with acute 
spontaneous intracerebral haemorrhage. Data are number (%), median [interquartile 
range] or mean (standard deviation). 
 
 All GTN No GTN Continue Stop 
Patients (N)      
Country, UK (%)      
Age (years)      
Sex, male (%)      
Smoking, current (%)      
Pre-morbid mRS =0 (%)      
Previous stroke (%)      
Prior antihypertensive drug use (%)      
Prior history of high BP (%)      
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Diabetes mellitus (%)      
Ischaemic heart disease (%)      
Atrial fibrillation (%)      
TACS (%)      
Scandinavian Stroke Scale (/58)      
Glasgow Coma Scale [/15]      
Systolic blood pressure (mmHg)      
Diastolic blood pressure (mmHg)      
Heart rate (bpm)      
Onset to neuroimaging (%)      
   <12 hours      
   12-24 hours      
    >24 hours      
Location of haematoma (%)      
   Lobar      
   Basal ganglia or thalamus      
   Brainstem      
   Cerebellum      
   Undetermined      
Longest diameter (cm)      
   <3      
   3-5      
   5-8      
   >8      
Leukoaraiosis      
Mass effect      
Remote ICH (%)      
Previous stroke lesion (%)      
Sub-arachnoid haemorrhage      
Sub-dural haemorrhage      
Extra-dural haemorrhage      
Measured CT scan findings      
Volume, ABC/2 (cm3)      
Diameter, max (cm)      
Diameter, max adjudicated (mode, cm)      
With IVH      
   Graeb score (/12) 36      
   Modified Graeb score (/32) 37      
   Volume (ml)      
Without IVH      
   Shape (/5) 53      
   Shape index      
   Density (/5) 53      
   Mean density      
   SD      
   Density index      
 
bpm: beats per minute 
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Table 2. Effect of interventions on imaging outcomes at day 7 
Effect of GTN vs no GTN, and continue vs stop temporarily pre-stroke 
antihypertensive agents, on imaging outcomes at day 7. Data are number (%), 
median (interquartile range) or mode. Comparisons by binary logistic regression, 
ordinal logistic regression or multiple linear regression, with adjustment for age; sex; 
history of hypertension; previous stroke; diabetes mellitus; current use of nitrate 
therapy (not for continue vs stop); stroke severity (SSS); total anterior circulation 
syndrome; systolic BP; baseline variable, and time from onset to randomisation. 
 
 
 
Table 3. Effect of interventions on clinical outcomes 
Effect of GTN vs no GTN, and continue vs stop temporarily pre-stroke 
antihypertensive agents, on clinical outcomes. Data are number (%), median 
(interquartile range) or mean (standard deviation). Comparisons by binary logistic 
regression, ordinal logistic regression or multiple linear regression, with adjustment 
for age; sex; history of hypertension; previous stroke; diabetes mellitus; current use 
of nitrate therapy (not for continue vs stop); stroke severity (SSS); total anterior 
circulation syndrome; systolic BP; and time from onset to randomisation. 
 
 All GTN No GTN OR/ß Continue Stop OR/ß 
Day 7        
Patients (N)        
Death (%)        
Death or deterioration (%)        
SSS (/58)        
Recurrence (%)        
SBP (mmHg)        
Imaging 
parameter 
GTN No 
GTN 
Difference 
(95% CI) 
p Continue Stop Difference 
(95% CI) 
p 
Patients (N)         
Volume (ABC/2), 
absolute (ml) 
        
Volume (ABC/2), 
relative (%) 
        
Diameter, max 
(cm) 
        
Diameter, max – 
adjudicated (cm) 
        
Mean radial 
expansion > 1mm 
        
No IVH, number 
(N) 
        
   Shape [/5]         
   Shape index         
   Density [/5]         
   Mean density         
   Density index         
IVH, number (N)         
   Graeb [/12]         
   Modified Graeb 
[/32] 
        
   IVH volume (ml)         
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Hospital events        
Patients (N)        
Death (%)        
Length of stay (days)        
Home (%)        
        
Day 90        
Patients (N)        
Death (%)        
Modified Rankin Scale (/6)        
Barthel Index (/100)        
tMMSE (/16)        
TICS (/39)        
Animal naming (/∞)        
ZDS (/100)        
HUS (EQ-5D) (/1)        
EQ-VAS (/100)        
 
 
Figure 1. Death by treatment group 
Forest plot for hazard of death (calculated by Cox regression) with 95% confidence 
intervals at day 90 by pre-specified baseline covariates (as listed in section 4.4.3) for 
(a) GTN vs no GTN; and (b) continue vs stop pre-stroke antihypertensive medications. 
 
 
Figure 2. Functional outcome by treatment group 
Forest plot for odds ratio of mRS (calculated by ordinal logistic regression) with 95% 
confidence intervals at day 90 by pre-specified baseline covariates (as listed in section 
4.4.3) for (a) GTN/no GTN; and (b) continue/stop pre-stroke antihypertensive 
medications. 
 
 
Figure 3. Survival by treatment group 
Kaplan-Meier plot for survival for (a) GTN/no GTN; and (b) continue/stop pre-stroke 
antihypertensive medications. 
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APPENDIX H. PLANNED PUBLICATION: HAEMODYNAMIC EFFECTS OF GTN 
VERSUS NO GTN, AND CONTINUE VERSUS STOP PRE-STROKE 
ANTIHYPERTENSIVE MEDICATIONS 
 
Authorship 
…, Philip Bath 
 
Title 
Effect of glyceryl trinitrate and/or continuing pre-stroke antihypertensive medications 
on blood pressure and other haemodynamic parameters, and relationship between 
changes and functional outcome. 
 
Aim 
To assess the effect of GTN vs no GTN, and continue vs stop temporarily pre-stroke 
antihypertensive medications, on blood pressure, heart rate and their derivatives in 
patients with acute stroke. 
 
Patients 
All randomised patients with acute stroke, by intention-to-treat. Haemodynamic 
measures will be calculated as in appendix B, section 2.2. 
 
Table 1. Baseline haemodynamic parameters 
Baseline haemodynamic parameters by treatment assignment. Data are number (%) 
or mean (standard deviation). 
 
 All GTN No GTN Continue Stop 
Patients (N)      
SBP, mean (mmHg)      
SBP, peak (mmHg)      
SBP, intra-visit variability (mmHg)      
SBP, CV (%)      
DBP, mean (mmHg)      
DBP, peak (mmHg)      
DBP, intra-visit variability (mmHg)      
DBP, CV (%)      
HE, mean (bpm)      
HR, peak (bpm)      
HR, intra-visit variability (bpm)      
HR, CV (%)      
Mean arterial pressure (MAP) (mmHg)      
Mean pressure (MP) (mmHg)      
Pulse pressure (PP) (mmHg)      
Pulse pressure index (PPI) (%)      
Rate-pressure product (RPP) (mmHg.bpm)      
 
 
Table 2. Effect of interventions on haemodynamic variables 
Effect of GTN vs no GTN, and continue vs stop pre-stroke antihypertensive agents, on 
haemodynamic variables at day 1, and over the first 4 days of treatment. Comparison 
by multiple logistic regression adjusted for baseline. 
 
 GTN No 
GTN 
Difference 
(95% CI) 
p Continue Stop Difference 
(95% CI) 
p 
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Day 1         
Patients (N)         
SBP, mean (mmHg)         
SBP, peak (mmHg)         
SBP, intra-visit 
variability (mmHg) 
        
SBP, CV (%)         
DBP, mean (mmHg)         
DBP, peak (mmHg)         
DBP, intra-visit 
variability (mmHg) 
        
DBP, CV (%)         
HE, mean (bpm)         
HR, peak (bpm)         
HR, intra-visit 
variability (bpm) 
        
HR, CV (%)         
Mean arterial 
pressure (MAP) 
(mmHg) 
        
Mean pressure (MP) 
(mmHg) 
        
Pulse pressure (PP) 
(mmHg) 
        
Pulse pressure 
index (PPI) (%) 
        
Rate-pressure 
product (RPP) 
(mmHg.bpm) 
        
         
Days 0-4         
Patients (N)         
Mean SBP across 
days 1-4 (mmHg) 
        
Inter-visit 
Variability (SBP-
inter SD) (mmHg) 
        
CV SBP across days 
0-4 (%) 
        
SBP peak across 
days 0-4 (mmHg) 
        
 
 
Figure 1. Change in SBP by 6 treatment groups 
Profile in mean SBP over 7 days of treatment by 6 treatment groups: a) 
GTN/continue, b) GTN/stop, c) no GTN/continue, d) no GTN/stop, e) GTN/no pre-
stroke agent, f) no GTN/no pre-stroke agent. Data are mean (standard deviation). 
Comparison of area under curves with ANOVA with adjustment for multiple 
comparisons. 
 
 
Figure 2. Outcome by change in SBP 
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Distribution in functional outcome (mRS) at day 90, by magnitude of change in mean 
SBP and variability between day 1 and 0, grouped as: increase/no change, and small 
decrease, moderate decrease, large decrease (with the latter 3 groups divided equally 
into tertiles). The ‘small decrease’ group will act as the reference.54 Data are number 
(%). Comparison by ordinal logistic regression adjusted for age; sex; stroke severity 
(SSS); total anterior circulation syndrome; stroke pathological type (unknown, IS, 
ICH); treated with rt-PA prior to randomisation; and time from onset to 
randomisation. 
 
mRS 0 1 2 3 4 5 Death 
Change in SBP        
Increase/no        
Small decrease        
Moderate decrease        
Large decrease        
        
Change in variability        
Increase/no        
Small decrease        
Moderate decrease        
Large decrease        
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APPENDIX I. PLANNED PUBLICATION: GTN, HEADACHE AND OUTCOME 
 
Authorship 
Kailash Krishnan, …, Philip Bath 
 
Title 
Relationship of GTN-related headache with outcome (as in PRoFESS  – submitted) 
 
Background 
The PRoFESS mega-trial found that the headache that occurs with dipyridamole - a 
nitric oxide modifying drug – is associated with less recurrence after ischaemic stroke 
[publication submitted]. Since the headache that occurs with GTN is mediated by a 
similar mechanism, GTN-associated headaches may also be associated with 
subsequent outcome. 
 
Hypotheses 
• The presence of a headache by day 7 in patients taking GTN is associated with a 
better functional outcome and less recurrence than those with out a headache. 
• The presence of a headache by day 7 in patients taking control is not associated 
with outcome. 
 
Patients 
All ENOS patients who received at least their first treatment (GTN/no GTN), who have 
information on headache (yes/no) at day 7, and who have functional outcome (mRS) 
recorded at day 90. SAEs for headache within the first 7 days will be validated against 
data for headache on the day 7 form. 
 
Table 1. Baseline table 
Baseline characteristics for patients with and without a headache by day 7, by 
treatment group. Data are number (%) or mean (standard deviation). Comparison by 
Chi-square or t test 
 GTN  2p No  GTN 2p 
Headache Yes No  Yes No  
N       
Age (years)       
Sex, male (%)       
Smoker, current (%)       
Alcohol, excess (%)       
Hypertension (%)       
Diabetes (%)       
Stroke (%)       
Ischaemic heart disease (%)       
Atrial fibrillation (%)       
Peripheral vascular disease (%)       
Severity (SSS, /58)       
TACS (%)       
SBP (mmHg)       
DBP (mmHg)       
Heart rate (bpm)       
 
Table 2. Outcome table 
Relationship between outcome and presence of a headache by day 7, by treatment 
group. Data are number (%) or mean (standard deviation), and odds ratio or ß-
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coefficient (95% confidence intervals). Comparison within treatment groups by binary 
logistic regression, ordinal logistic regression, multiple linear regression or Cox 
regression. 
 GTN  OR/ß No GTN OR/ß 
Headache Yes No  Yes No  
Day 7       
Patients (N)       
Death (%)       
Deterioration or death (%)        
Ischaemic stroke       
   Recurrence (%)       
   sICH (%)       
SSS (/58)       
       
Hospital events       
Patients (N)       
Length of stay (days)       
Death (%)       
       
Day 90       
Patients (N)       
Death (%)       
Modified Rankin Scale (/6)       
Barthel Index (/100)       
tMMSE (/16)       
TICS (/100)       
Animal naming (/∞)       
ZDS (/100)       
HUS (EQ-5D) (/1)       
EQ-VAS (/100)       
 
 
Figure 1. Survival 
Survival curves for patients with and without headache by day 7, by treatment group. 
Comparison within treatment groups by Cox regression. 
 
 
Figure 2. Functional outcome 
Modified Rankin Scale at day 90 for patients with and without headache by day 7, by 
treatment group. Data are number (%). Comparison within treatment groups by 
ordinal logistic regression. 
 
mRS 0 1 2 3 4 5 Death 
GTN        
Headache        
No headache        
        
No GTN        
Headache        
No headache        
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APPENDIX J. PLANNED PUBLICATION: EFFECT OF GTN ON FEEDING STATUS 
 
Authorship 
…, Shaheen Hamdy, David Smithard, David Cohen, … Niki Sprigg, Philip Bath 
 
Title 
Effect of transdermal glyceryl trinitrate on feeding status at day 7 after stroke, and 
relationship of feeding status with functional outcome: results from the ‘Efficacy of 
Nitric Oxide in Stroke’ (ENOS) trial. 
 
Hypothesis 
GTN relaxes smooth muscle and therefore may improve the oesophageal phase of 
swallowing. A small/pilot randomised trial of nifedipine, a calcium channel blocker that 
also relaxes oesophageal smooth muscle, reported potentially beneficial effects.55 
 
Patients 
Patients in ENOS with information on feeding status at both baseline and day 7, and a 
final diagnosis of strokes. Analysis by intention-to-treat. 
Feeding status is defined on a 6-level ordered categorical scale (normal diet, soft diet, 
nasogastric tube fed, PEG-tube fed, iv/sc fluids, no feeding/fluids). 
Since dysphagia was not directly assessed, dysphagia is defined clinically as patients 
who cannot take fluids/food orally, i.e.: 
• Not dysphagic/oral feeding: normal diet, soft diet 
• Dysphagic/no oral feeding: NGT-feeding, PEG/RIG-feeding, iv/sc fluids or no 
feeding/fluids 
• Missing data - No information on feeding status 
 
Table 1. Baseline data 
Characteristics of patients with and without clinical dysphagia at baseline. Data are 
number (%) or mean (standard deviation). Comparison of patients who have versus 
do not have oral feeding by Chi-square test or t test. 
 
 All GTN No 
GTN 
No oral 
feeding 
Oral 
feeding 
Difference 
(95% CI) 
2p 
Number of participants        
Age (years)        
Sex, male (%)        
Stroke, previous (%)        
Hypertension (%)        
Ischaemic heart disease (%)        
Scandinavian Stroke Scale 
(/58) 
       
Systolic blood pressure 
(mmHg) 
       
Ischaemic stroke (%)        
Time to randomisation 
(hours) 
       
Stroke syndrome (%)        
   TACS        
   PACS        
   POCS        
   LACS        
Stroke type, ischaemic (%)        
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Feeding status (%)        
   Normal diet    -   - 
   Soft diet    -   - 
   NGT-fed     -  - 
   PEG-fed     -  - 
   Intravenous/subcutaneous 
fluids 
    -  - 
   No feeding fluids     -  - 
 
 
Table 2a. Change in feeding status 
Change in feeding status from baseline to day 7 for patients randomised to GTN. Data 
are number (%). 
 
Baseline Normal 
diet 
Soft 
diet 
NGT-
fed 
PEG-
fed 
Iv/sc 
fluids 
No 
feeding/fluids 
Missing 
data 
Day 7        
Normal diet        
Soft diet        
NGT-fed        
PEG-fed        
Iv/sc fluids        
No 
feeding/fluids 
       
Death        
Missing data        
 
 
Table 2b. Change in feeding status 
Change in feeding status from baseline to day 7 for patients randomised to no GTN. 
Data are number (%). 
 
Baseline Normal 
diet 
Soft 
diet 
NGT-
fed 
PEG-
fed 
Iv/sc 
fluids 
No 
feeding/fluids 
Missing 
data 
Day 7        
Normal diet        
Soft diet        
NGT-fed        
PEG-fed        
Iv/sc fluids        
No 
feeding/fluids 
       
Death        
Missing data        
 
Table 3 Outcomes by GTN/no GTN 
Effect of GTN vs no GTN on feeding status at day 7 in subgroups defined at baseline. 
Data are odds ratio (95% confidence intervals) and interaction test. Comparison by 
ordinal logistic regression. This table may be presented as a Forest plot. 
 
Variable GTN No GTN OR (95% CI) Interaction p 
Age, <70     
Age, >70    - 
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Sex, female     
Sex, male    - 
Previous stroke, no     
Previous stroke, yes    - 
Stroke syndrome, LACS     
Stroke syndrome, PACS    - 
Stroke syndrome, POCS    - 
Stroke syndrome, TACS    - 
Stroke severity, SSS >40     
Stroke severity, SSS 30-40    - 
Stroke severity, SSS <30    - 
Stroke, ischaemic     
Stroke, ICH    - 
Feeding, oral     
Feeding, not oral    - 
Time to randomisation, <6     
Time to randomisation, 6.1-12    - 
Time to randomisation, 12.1-24    - 
Time to randomisation, 24.1-36    - 
Time to randomisation, 36.1-48    - 
Treatment, alteplase     
Treatment, no alteplase    - 
All patients      
 
 
Table 4. Outcomes by dysphagia/no dysphagia 
Comparison of outcomes at days 7 and 90 by swallowing status at baseline. Data are 
number (%) or mean (standard deviation), and odds ratio/ß-coefficient (95% 
confidence intervals). Comparison by binary logistic regression, ordinal logistic 
regression, or multiple linear regression, with adjustment for age, sex, previous 
stroke, severity, stroke pathological type, time, treatment assignment (GTN/no GTN). 
 
 N All patients No oral feeding Oral feeding OR/ß 
Day 7      
Patients (N)      
Death (%)      
Death or deterioration (%)      
SSS (/58)      
Recurrence (%)      
SAEs, all (%)      
   Pneumonia      
      
Hospital events      
Patients (N)      
Death (%)      
Length of stay (days)      
Home (%)      
      
Day 90      
Patients (N)      
Death (%)      
Modified Rankin Scale (/6)      
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Barthel Index (/100)      
tMMSE (/16)      
TICS (/39)      
Animal naming (/∞)      
ZDS (/100)      
HUS (EQ-5D) (/1)      
EQ-VAS (/100)      
SAEs, all (%)      
   Pneumonia      
 
 
Figure 1. Feeding status at day 7 
Shift in feeding status at day 7 by treatment with GTN vs no GTN. Data are number 
(%). Comparison by ordinal logistic regression adjusted for age, sex, stroke severity 
(SSS), TACS, stroke pathological type (unknown, IS, ICH), SBP, time between stroke 
and randomisation, and baseline feeding status. 
Feeding 
status 
Normal 
diet 
Soft diet NGT-fed PEG-fed Iv/sc 
fluids 
No 
feeding/fluids 
GTN       
No GTN       
 
 
Figure 2. Modified Rankin Scale at day 90 
Shift in modified Rankin Scale at day 90 between patients who were dysphagic (no 
oral feeding) versus those who were not (oral feeding). Data are number (%). 
Comparison by ordinal logistic regression adjusted for age, sex, stroke severity (SSS), 
TACS, stroke pathological type (ICH, ischaemic), SBP, time for onset to 
randomisation, baseline feeding status and treatment assignment. 
 
mRS 0 1 2 3 4 5 Death 
Dysphagia        
No 
dysphagia 
       
 
 
Figure 3. Dysphagia in sub-groups 
Forrest plot of feeding status in pre-specified sub-groups, as listed in table 3. 
 
 
Figure 4. Survival 
Survival curve for dysphagia vs no dysphagia for (a) all patients to 100 days, and (b) 
UK patients to 4000 days. Comparisons by Cox regression adjusted for age, sex, 
stroke severity (SSS), TACS, stroke pathological type (ICH, ischaemic), SBP, time 
between stroke and randomisation, baseline feeding status and treatment 
assignment. 
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APPENDIX K. PLANNED PUBLICATION: SPONTANEOUS INTRACEREBRAL 
HAEMORRHAGE BETWEEN DIFFERENT WORLD REGIONS 
 
Authorship 
Kailash Krishnan, …, Niki Sprigg, Joanna Wardlaw, Philip Bath 
 
Title 
Comparison of acute spontaneous intracerebral haemorrhage between different world 
regions: patients, haematoma and outcomes in the ENOS trial. 
 
Authors 
To include neuroimaging adjudicators and K Krishnan. 
 
Aim 
To compare patients and haematoma characteristics, and outcomes, between different 
regions of the world. Approaches used in previous publications comparing stroke 
outcomes between countries 46,48,56 will be followed. 
 
Patients 
All randomised patients with acute spontaneous intracerebral haemorrhage, by 
intention-to-treat: 
a) Africa: Egypt 
b) America, north: Canada 
c) Asia, east: China, Hong Kong 
d) Asia, south: India, Sri Lanka     
e) Asia, south-east: Malaysia, Philippines, Singapore 
f) Australasia: Australia, New Zealand  
g) British Isles: Eire, UK 
h) Europe: Denmark, Georgia, Greece, Italy, Norway, Poland, Romania, Spain, 
Sweden 
 
 
Table 1. Baseline ICH characteristics 
Baseline demographic, clinical and neuroimaging characteristics of patients with 
spontaneous intracerebral haemorrhage. Data are number (%), median [interquartile 
range] or mean (standard deviation). 
 
 All Africa America, 
north 
Asia 
east 
Asia 
south 
Asia 
south-
east 
Austral-
asia 
British 
Isles 
Europe 
Patients (N)          
Age (years)          
Sex, male 
(%) 
         
Smoking, 
current (%) 
         
Pre-morbid 
mRS =0 (%) 
         
Previous 
stroke (%) 
         
Prior antiHT 
drug use (%) 
         
Prior history 
of high BP 
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(%) 
Diabetes 
mellitus (%) 
         
Ischaemic 
heart disease 
(%) 
         
Atrial 
fibrillation 
(%) 
         
TACS (%)          
Scandinavian 
Stroke Scale 
(/58) 
         
Glasgow 
Coma Scale 
[/15] 
         
SBP (mmHg)          
DBP (mmHg)          
HR (bpm)          
Onset to 
neuroimaging 
(%) 
         
   <12 hours          
   12-24 
hours 
         
    >24 hours          
          
Adjudicated 
parameters 
         
Location of 
haematoma 
(%) 
         
   Lobar          
   Basal 
ganglia or 
thalamus 
         
   Brainstem          
   Cerebellum          
Longest 
diameter 
(cm) 
         
   <3          
   3-5          
   5-8          
   >8          
Leukoaraiosis          
Mass effect          
Remote ICH 
(%) 
         
Previous 
stroke lesion 
(%) 
         
Sub-          
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arachnoid 
haemorrhage 
Sub-dural 
haemorrhage 
         
Extra-dural 
haemorrhage 
         
          
Measured CT 
scan findings 
         
Volume, 
ABC/2 (cm3) 
         
Diameter, 
max (cm) 
         
Diameter, 
max 
adjudicated 
(mode, cm) 
         
With IVH          
   Graeb score 
(/12) 36 
         
   Volume 
(ml) 
         
Without IVH          
   Shape (/5) 
53 
         
   Density 
(/5) 53 
         
 
bpm: beats per minute 
 
 
Table 2. Functional outcome 
Comparison of functional outcome at day 90 by world region. Data are number (%), 
median (interquartile range) or mean (standard deviation. Comparisons Chis-square 
test or Kruskal-Wallis test. by binary logistic regression, ordinal logistic regression or 
multiple linear regression, with adjustment for age; sex; history of hypertension; 
previous stroke; diabetes mellitus; stroke severity (SSS); total anterior circulation 
syndrome; systolic BP; ICH volume; time from onset to randomisation; GTN/no GTN; 
and continue/stop. 
 
 Al
l 
Afric
a 
America
, north 
Asia 
eas
t 
Asia 
sout
h 
Asia 
south
-east 
Austral
-asia 
Britis
h 
Isles 
Europ
e 
p 
Day 7           
Patients (N)           
Death (%)           
Death or 
deterioratio
n (%) 
          
Recurrence 
(%) 
          
SSS (/58)           
SBP           
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(mmHg) 
SAEs (%)           
   Cerebral 
oedema 
          
           
Hospital 
events 
          
Patients (N)           
Death (%)           
Home (%)           
Length of 
stay (days) 
          
           
Day 90           
Death (%)           
mRS (/6)           
BI (/100)           
tMMSE 
(/16) 
          
TICS (/39)           
Animal 
naming 
(/∞) 
          
ZDS (/100)           
HUS (EQ-
5D) (/1) 
          
EQ-VAS 
(/100) 
          
 
 
Figure 1. Death by country 
Forest plot for hazard of death (calculated by Cox regression) with 95% confidence 
intervals at day 90 by geographical region relative to the British Isles. For analyses 
(a) unadjusted; and (b) adjusted for age; sex; history of hypertension; previous 
stroke; diabetes mellitus; stroke severity (SSS); total anterior circulation syndrome; 
systolic BP; ICH volume; time from onset to randomisation; GTN/no GTN; and 
continue/stop. 
 
 
Figure 2. Functional outcome by country 
Forest plot for odds ratio of mRS (calculated by ordinal logistic regression) with 95% 
confidence intervals, at day 90 by geographical region relative to the British Isles. For 
analyses (a) unadjusted; and (b) adjusted for age; sex; history of hypertension; 
previous stroke; diabetes mellitus; stroke severity (SSS); total anterior circulation 
syndrome; systolic BP; ICH volume; time from onset to randomisation; GTN/no GTN; 
and continue/stop. 
 
 
Figure 3. Survival 
Kaplan-Meier plot for survival by geographical region. 
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APPENDIX L. PLANNED PUBLICATION: COMPARISON OF PATIENTS WHO 
TOOK VERSUS DID NOT TAKE PRE-STROKE ANTIHYPERTENSIVE 
MEDICATIONS: BASELINE CHARACTERISTICS AND OUTCOMES  
 
Authorship 
… 
 
Title 
Comparison of patients who took versus did not take pre-stroke antihypertensive 
medications: baseline characteristics and outcomes. 
 
Hypothesis 
Patients taking pre-stroke antihypertensive medications will have more vascular risk 
factors and a worse outcome than those not on such medications. 
 
Patients 
Patients with confirmed stroke, by intention to treat. 
 
Table 1. Baseline characteristics of included trials 
Description of the trials and their participants. Trials are ordered by mean time to 
recruitment. Data are number (%) or mean (standard deviation). 
 
Table based on baseline data publication. 
 
Table 2. Outcomes 
Comparison of outcomes in patients taking versus not taking pre-stroke 
antihypertensive medications. 
 Analysis   OR/ß 
Pre-stroke antihypertensive medications  Yes No  
Day 7     
Patients (N)     
Death (%)     
Death or deterioration (%)      
Ischaemic stroke     
   Recurrence (%)     
   sICH (%)     
SSS (/58)     
     
Hospital events     
Patients (N)     
Death (%)     
Length of stay (days)     
     
Day 90     
Patients (N)     
Death (%)     
Modified Rankin Scale (/6)     
Barthel Index (/100)     
tMMSE (/16)     
TICS     
Animal naming (/∞)     
ZDS (/100)     
HUS (EQ-5D) (/1)     
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EQ-VAS (/100)     
 
 
Figure 1. Modified Rankin Scale at day 90 
Shift in modified Rankin Scale at day 90 between patients who took versus did not 
take pre-stroke antihypertensive medications. Data are number (%). Comparison by 
ordinal logistic regression adjusted for age, sex, geographical region, hypertension, 
hyperlipidaemia, diabetes mellitus, atrial fibrillation, previous stroke, previous TIA, 
ischaemic heart disease, smoking, pre-morbid mRS, stroke severity (SSS), GCS, 
TACS, stroke pathological type (ICH, ischaemic), SBP, time for onset to 
randomisation, baseline feeding status, and GTN vs no GTN. 
 
mRS 0 1 2 3 4 5 Death 
Yes        
No        
 
 
Figure 2. Survival by day 90 
Survival curve between patients who took versus did not take pre-stroke 
antihypertensive medications. Comparisons by Cox regression adjusted for age, sex, 
geographical region, hypertension, hyperlipidaemia, diabetes mellitus, atrial 
fibrillation, previous stroke, previous TIA, ischaemic heart disease, smoking, pre-
morbid mRS, stroke severity (SSS), GCS, TACS, stroke pathological type (ICH, 
ischaemic), SBP, time for onset to randomisation, baseline feeding status, and GTN vs 
no GTN. 
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APPENDIX M. PLANNED PUBLICATION: TEMPORAL EFFECTS OF GTN ON 
FUNCTIONAL OUTCOME 
 
Authorship 
…, Sandeep Ankolekar, Tim England, Kailash Krishnan, Parveen Rashid, Gill Sare, Niki 
Sprigg, Mark Willmot, Philip Bath 
 
Title 
Effect of transdermal glyceryl trinitrate on functional outcome in acute stroke by time 
to treatment: an individual patient data meta-analysis of all ultra-acute, acute, and 
subacute randomised trials of GTN. 
 
Hypothesis 
The effect of GTN on functional outcome may vary by time to treatment, as with 
alteplase.57 
 
Patients 
All patients in GTN-1/2/3, RIGHT, ENOS and any other identified randomised 
controlled trials of GTN,10-13 by intention to treat. The publication will follow the 
approaches published for alteplase.57,58 
 
Table 1. Baseline characteristics of included trials 
Description of the trials and their participants. Trials are ordered by mean time to 
recruitment. Data are number (%) or mean (standard deviation). 
Trial All GTN No 
GTN 
GTN-
110 
GTN-2 
11 
GTN-3 
12 
RIGHT 
13,14 
ENOS 
15 
GTN dose         
Onset  (hr)         
Number         
Age (years)         
Sex, male (%)         
Previous stroke (%)         
Hypertension (%)         
Diabetes mellitus 
(%) 
        
Ischaemic heart 
disease (%) 
        
Atrial fibrillation (%)         
Severity (SSS, /58)         
SBP (mmHg)         
DBP (mmHg)         
Heart rate (bpm)         
Ischaemic stroke (%)         
OTR (hr)         
 
 
Table 2. Outcome by time 
Effect of GTN vs no GTN on outcomes by time epochs from stroke onset to 
randomisation (OTR). Data are odds ratio or beta coefficients (with 95% confidence 
intervals). Comparison between GTN vs no GTN by binary logistic regression, ordinal 
logistic regression, multiple regression or Cox regression, with adjustment for age, 
sex, severity (Scandinavian Stroke Scale), stroke pathological type (ischaemic, ICH), 
systolic blood pressure. 
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OTR (hr) All <4 4.1-8 8.1-12 12.1-24 24.1-48 48.1-96 >96 
End-of-treatment         
Patients (N)         
Death (%)         
Death/deterioration (%)         
Recurrence (%)         
SSS (/58)         
         
Discharge         
Patients (N)         
Death (%)         
Home (%)         
Length of stay (days)         
         
Day 90         
Death (%)         
mRS (/6)         
BI (/100)         
tMMSE (/16)         
TICS (/39)         
Animal naming (/∞)         
ZDS (/100)         
HUS (EQ-5D) (/1)         
EQ-VAS (/100)         
 
 
Table 3. Numbers-needed-to-treat by time 
Numbers-needed-to-treat 59 by time epochs from stroke onset to randomisation 
(OTR). Data are NNT (with 95% confidence intervals) with adjustment for age, sex, 
severity (Scandinavian Stroke Scale), stroke pathological type (unknown, IS, ICH), 
systolic blood pressure. 
OTR (hr) All <4 4.1-8 8.1-12 12.1-24 24.1-48 48.1-96 >96 
Day 90         
Death         
mRS         
 
 
Figure 1. Meta-analysis of trials 
Forrest plot of meta-analysis of GTN trials. 
 
 
Figure 2. Outcome by time-to-treatment 
Relationship between outcome at day 90 and time from onset to randomisation, for 
(a) modified Rankin Scale (odds ratio for 7 level scale); (b) death (odds ratio); (c) 
Zung Depression Scale (ß-coefficient); and (d) Health Utility Status (derived from EQ-
5D, ß-coefficient). 
 
 
Figure 3. Functional outcome 
Distribution of modified Rankin Scale for GTN vs no GTN by time from stroke to 
randomisation for time epochs (hours): <4, 4.1-8, 8.1-12, 12.1-24, 24.1-48, 48.1-96, 
>96. 
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APPENDIX N. PLANNED PUBLICATION: CONTINUING VERSUS STOPPING PRE-
STROKE ANTIHYPERTENSIVE MEDICATIONS IN ACUTE STROKE: A META-
ANALYSIS OF INDIVIDUAL PATIENT DATA FROM RANDOMISED CONTROLLED 
TRIALS 
 
Authorship 
Tom Robinson, …, Ken Lees, Philip Bath 
 
Title 
Comparison of continuing or temporary stopping of pre-stroke antihypertensive 
medication in acute stroke: a prospective meta-analysis of individual patient data 
from randomised controlled trials. 
 
Hypothesis 
Continuing pre-stroke antihypertensive therapy lowers BP and reduces poor functional 
outcome as opposed to temporary stopping of such treatment. 
 
Patients 
Patients recruited into trials comparing continuing versus stopping pre-stroke 
antihypertensive agents in patients with acute stroke, with analysis by intention to 
treat. The publication will follow the approaches published for alteplase.57,58 
 
Table 1. Included trials 
Characteristics of trials comparing continuing versus stopping pre-stroke 
antihypertensive medication in patients with acute stroke. 
 
 Size Recruitment 
time window 
(hrs) 
Length of 
treatment 
(days) 
Length 
of 
follow-
up 
(days) 
SBP 
range 
(mmHg) 
Major exclusions 
COSSACS 
49 
763 < 48 14 180 >100 Need for 
antihypertensive 
agents 
ENOS 15 ? <48 7 90 140-220 Need for GTN or 
antihypertensive 
agents 
Other 
trial(s)? 
      
GTN: glyceryl trinitrate 
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Table 2. Baseline characteristics 
Baseline characteristics of trial participants. Data are number (%) or mean (standard 
deviation). Comparison by Chi-square test or ANOVA. 
 
 COSSACS 
49 
ENOS 
15 
Other trial(s) 
? 
P-
value 
No. of patients     
Age (years)     
Sex, male (%)     
Race-ethnicity (%) [1]     
   Caucasian     
   Asia, east     
   Asia, south     
   Asia, south-east     
   Other     
Medical history (%)     
   Hypertension     
   Diabetes mellitus     
   Hyperlipidaemia     
   Atrial fibrillation     
   Previous stroke     
   TIA     
   Ischaemic heart disease     
   Family history of stroke     
   Smoker, current     
Rankin Scale, pre-morbid 0     
Antihypertensive agents pre-stroke     
   Angiotensin converting enzyme 
inhibitor 
    
   Angiotensin receptor antagonist     
   Renin inhibitor     
   ß-receptor antagonist     
   Calcium channel blocker     
   Diuretic     
   α-receptor antagonist     
   Centrally acting     
   Other     
Number of antihypertensive agents     
   1     
   2     
   3     
   4     
   >4     
Time since last BP drugs     
Medications, other pre-stroke     
   Aspirin     
   Dipyridamole     
   Clopidogrel     
   Statin     
Haemodynamic measures     
   Systolic BP (mmHg)     
   Diastolic BP (mmHg)     
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   Pulse pressure (mmHg)     
   Systolic BP, peak (mmHg)     
   Systolic BP, standard deviation 
(mmHg) 
    
   Heart rate (bpm)     
   Rate-pressure product (mmHg.bpm)     
Stroke severity, NIHSS [2]     
Stroke type/aetiology (%)     
   IS [3]     
   ICH     
   Stroke type unknown     
   Non stroke     
Stroke syndrome (%)     
   Total anterior circulation     
   Partial anterior circulation     
   Posterior circulation     
   Lacunar     
Stroke aetiology (if ischaemic) (%)     
   Small vessel     
   Large artery     
   Cardioembolic     
   Other     
Carotid stenosis, ipsilateral 70-99% 
[4] 
    
Time to randomisation (hr) (%)     
   <12     
   13-24     
   25-48     
1. ENOS: Race-ethnicity defined by country of recruitment 
2. ENOS: NIHSS estimated from Scandinavian Stroke Scale 35 
3. Infarct: normal imaging or infarct with/without haemorrhagic transformation 
4. COSSACS: Symptomatic carotid stenosis from SAE reporting carotid 
endarterectomy 
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Table 3. Outcomes 
Functional outcome and vascular events. Percentage for continue versus stop; comparison by logistic regression, or multiple 
regression, adjusted for trial, age, sex, severity, systolic blood pressure. 
 
Outcome COSSACS  ENOS  Other 
trial? 
 All 
stroke 
OR 
(95% 
CI) 
P-
value 
IS 
OR 
(95% 
CI) 
P-
value 
ICH 
OR 
(95% 
CI) 
P-
value 
 Continue Stop Continue Stop Continue Stop       
Patients             
End of treatment [1]             
   Death (%)             
   Recurrence (%)             
      Ischaemic             
      Haemorrhagic             
      Unknown             
   Death or 
deterioration (%) 
            
   Impairment, NIHSS 
[2]  
            
   Systolic BP             
   Diastolic BP             
End of trial [3]             
   Death (%)             
   mRS>2 (%)             
   Stroke (%) [4]             
   Myocardial infarction 
(%) [4] 
            
   Vascular event (%) 
[5]  
            
Lost to follow-up (%)             
1. COSSACS: 14 days; ENOS: 7 days 
2. ENOS: NIHSS estimated from Scandinavian Stroke Scale 40 
3. COSSACS: 180 days; ENOS: 90 days 
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4. ENOS (end of follow-up): Stoke and MI rates obtained from serious adverse events 
5. Composite of vascular death, non-fatal stroke, and non-fatal myocardial infarction 
 
CONFIDENTIAL: ENOS SAP GTN V1.0 
 Page 76 of 80 
 
Blood pressure profile 
 
Figure 1. Blood pressure during 7 days of treatment. ΔSBP and ΔDBP signify mean 
difference in systolic and diastolic blood pressure between the two groups; p values were 
calculated with the independent sample t test, and are for difference in systolic blood 
pressure between groups. 
 
 
 
 
 
Modified Rankin Scale distribution 
 
Figure 2. Modified Rankin Scale (mRS) at 90 days follow-up. Distribution of mRS scores 
by treatment group. Comparison by ordinal logistic regression adjusted for baseline 
factors. 
 
 
 
 
 
Primary outcome in pre-specified subgroups 
 
Figure 3. Subgroup analysis of effects on functional outcome at 90 days. Pre-defined 
subgroups are listed in section 4.4.3. 
 
 
 
 
Survival curves 
 
Figure 4. Cumulative hazard of (a) death; (b) recurrence; and (c) cardiovascular events 
during follow-up. Cox proportional regression with adjustment for baseline covariates, 
hazard ratio=  (95% CI  - ), p= . 
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